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Lisa M. Kardos 
The role of the biological receptor is currently being studied by researchers in medicine. 
Information about sigma receptors in particular can be gained by studying the ligands 
associated with each type, sigma 1 or sigma 2.  Sigma 1 receptor ligands consist of drug 
candidates that often have psychiatric and neurological applications; sigma 2 receptor 
ligands consist of drug candidates that have been linked with cancer treatment among 
other applications.  
Molecular modeling of biological receptor ligands often encompasses 
pharmacophore development and Comparative Molecular Field Analysis (CoMFA). 
Pharmacophore models are developed to understand the unique features such as binding 
groups that make a ligand bioactive. CoMFA uses experimental data of molecules, 
considered to be a training set, to yield bioactivity prediction for those molecules; this is 
the internal validation piece. An external test set of molecules with known experimental 
data can then be used for validation of the CoMFA models. The resulting CoMFA 
models create contour maps which provide information about the sterics and 
electrostatics, resulting in the ability to apply this information during the design of new 
ligands. The new molecules can then be tested in the validated CoMFA models to yield 
bioactivity predictions. 
ii
This study describes the development of pharmacophore and Comparative 
Molecular Field Analysis (CoMFA) models for sigma 1 and sigma 2 receptor ligands. 
Distance Comparisons (DISCOtech) in SYBYL-X 2.1 is used as a tool for the 
pharmacophore development. A pharmacophore is developed for each individual class of 
molecules and for the entire set of sigma 1 molecules and sigma 2 molecules analyzed 
during this study, respectively. All compounds are calculated in SPARTAN ’14 using ab 
initio and density functional calculation methods HF/6-31G* and B3LYP/6-31G* prior to 
model development. These calculations determine the geometry optimization and 
electrostatic charges for each molecule.  
 CoMFA studies, utilizing SYBYL-X 2.1, are performed for 41 sigma 1 receptor 
ligands using the radioligand [H
3
](+) pentazocine and for 31 sigma 2 receptor ligands 
using [H
3
](+) DTG in the presence of pentazocine. The CoMFA models developed 
confirm that bioactivity prediction comparison is reliable for both HF/6-31G* and 
B3LYP/6-31G* optimized geometries for both sigma 1 and sigma 2 ligands; this is 
verified via both internal and external validation methods. The CoMFA contour maps are 
utilized to design new sigma 1 and sigma 2 ligands; the newly designed ligands are 
predicted to be highly active according to the CoMFA models. This study also compares 
CoMFA models between the ab initio and density functional calculation levels for sigma 
1 and sigma 2 ligands, respectively. The similarities and differences between sigma 1 and 
sigma 2 receptor ligands are also analyzed via the developed pharmacophore models and 
generated CoMFA contour maps.  
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Chemical engineering and chemistry as disciplines interestingly converge at certain 
points. In this particular study, this convergence occurs conceptually with molecular 
modeling related drug design as it pertains to chemical reaction kinetics and 
thermodynamics. These are the same fundamentals which drive the interaction of 
biological receptors and their ligands; the binding of ligands to receptors results in a 
cascade of biological and medicinal activity, hence the usefulness in designing drugs 
targeted to receptors (Sharma, 2012).  
Sigma receptors have become key therapeutic targets in biological and medicinal 
chemistry studies. Sigma receptors are considered to be a unique receptor family that is 
localized in the cell cytoplasm of the brain; internal organs; and endocrine, immune and 
reproductive tissues and they are overexpressed by several tumor cell lines (Berardi et al., 
2004). There are two sub-types that are currently identified in the literature, sigma 1 and 
sigma 2. Receptor ligands, particularly highly active ones, are critical since binding leads 
to biological effects (Patrick, 2005). The sigma 1 subtype is involved in socially 
important human diseases such as schizophrenia, depression, Alzheimer’s disease and 
drug/alcohol dependence (Brune and Wünsch, 2013). The sigma 1 receptor is also being 
studied for the treatment of several pain conditions, either alone or in combination with 
known analgesics (Zamanillo et al., 2013). The sigma 2 subtype is currently being studied 





Berardi et al., 2004).  
Computers have become an essential tool in modern medicinal chemistry and are 
important in both drug discovery and drug development (Patrick, 2005).  Molecular 
modeling, including methods such as quantum mechanics, pharmacophore derivation and 
CoMFA (Comparative Molecular Field Analysis), yielded results for the following 
objectives: 
1) Derive  pharmacophore models for each selected series of active sigma 1 
ligand classes  
 
2) Derive a representative (comprehensive) pharmacophore for the selected 
sigma 1 ligand series 
 
3) Perform an alignment of 41 compounds to construct a validated CoMFA for 
sigma 1 receptor ligands. 
 
4) Compare density functional and ab initio calculations to the CoMFA studies 
on sigma 1 ligands. 
 
5) Predict the bioactivities (binding affinities) of the selected sigma 1 receptor 
ligands. 
 
6) Design new sigma 1 ligands (potential drug candidates) from CoMFA results. 
 
7) Derive pharmacophore models for each selected series of active sigma 2 
classes. 
 
8) Derive a representative (comprehensive) pharmacophore for the selected 
sigma 2 series. 
 
9) Perform an alignment of 31 compounds to construct a validated CoMFA for 
sigma 2 receptor ligands.  
 
10) Compare density functional and ab initio calculations to the CoMFA studies 
on sigma 2 ligands. 
 
11) Predict the bioactivities (binding affinities) of the selected sigma 2 receptor 
ligands. 
 







13) Analyze the resulting pharmacophores and models determined by the 

























2.1 Biological Activity and Interactions of Receptor Ligands 
The term receptor has been formally defined as a cellular macromolecule that is 
concerned directly and specifically with chemical signaling between and within cells; the 
combination of an appropriate ligand with its receptor(s) initiates a change in cell 
function (Cannon, 2007). Essentially a ligand is a drug and the affinity is a measure of 
how strongly a drug binds to a receptor (Patrick, 2005).  The corresponding equation 
describing the drug-receptor relationship, Equation 2.1, along with the equation for Kd, 
Equation 2.2. the dissociation binding constant, are as follows (Silverman, 2004): 
 









The dissociation constant is a measure of the strength of the interaction between the drug 
candidate and the receptor (target); Kd is often referred to as the inhibition constant, Ki, 
for an enzyme inhibitor (Berg and Stryer, 2005).  It is important to note that the literature 
for sigma receptor ligands typically uses Ki to discuss the affinity values. After 
synthesizing drug targets, researchers use radioligand labelling where a ligand for the 
target receptor is labelled with radioactivity and is added to cells or tissue such that it can 





are removed thereby allowing measurement of radioactivity which relates to the extent of 
binding (Patrick, 2005). After data is collected from experiments and plotted, a 
displacement or inhibition curve can be generated to yield an IC50 value (Patrick, 2005). 
Some researchers use computer software to aid in this area in the literature. Note that IC50 
(or I50) expresses the concentration of inhibitor required to produce 50 percent inhibition 
of an enzymatic reaction (Cheng and Prusoff, 1973). Ki is the same as the IC50 value if 
non-competitive interactions are involved; for compounds that are in competition with 
the radioligand for the binding site, the Ki depends on the following equation (Cheng and 








Note that competitive inhibition is the focus of this study. Competitive inhibition means 
that the inhibitor binds to the same site on the enzyme as the substrate, forming an 
abortive complex; the substrate and inhibitor compete for the same site so that only one 
enzyme-inhibitor complex is possible (Cornish-Bowden, 1976). pKi is also a tool that has 
been used by the Gund group in previous work, particularly in CoMFA.  pKi is defined in 
Equation 2.4 as: 
 
pKi = -log[Ki] (2.4) 
 
The pKi values were calculated by the Ki values provided in the literature which were 





 The aforementioned information regarding the basic enzyme-type kinetics of 
receptor ligands explains a piece of the drug-receptor complex. It is important to note that 
the interactions involved in the drug-receptor complex are the same forces experienced 
by all interacting organic molecules and include covalent bonding, ionic (electrostatic) 
interactions, ion-dipole and dipole-dipole interactions, hydrogen bonding, charge-transfer 
interactions, hydrophobic interactions, and van der Waals interactions (Silverman, 2004).  
Electrostatic properties of the receptor ligands will be discussed and studied when the 
CoMFA studies are complete, whereas some of the structure-activity relationships with 
the hydrophobic groups within the receptor ligands, a key property of the pharmacophore 
models in this study, will be discussed in Chapters 3 and 4. 
 
2.2 Pharmacophore Identification and QSAR Methodology 
Pharmacophore identification for the ligands in this study is a key aspect of the research. 
Pharmacophores allow us to understand drug-receptor interactions on the molecular level 
especially if there is not much information about the structure of the receptors themselves 
(Höltje, 1996).   A pharmacophore represents the relative position of important binding 
groups in space and disregards the molecular structure that holds them there (Patrick, 
2005).  A majority of drugs exert their action via specific binding to biomacromolecules, 
hence the importance of the binding groups (Höltje, 1996).  Typical binding sites include 
hydrophobic groups, aromatic rings, positive nitrogen atoms, acceptor sites (lone pair of 
electrons), donor sites and others. 
When a pharmacophore has been identified, structures can be analyzed to 





this approach, while ensuring that there are no steric clashes with the binding site, will 
help identify the active structures (Patrick, 2005). It is important to note that this process 
can be conducted manually or via a software program. This study uses the SYBYL suite 
which includes DISCOtech (DIStance COmparison) which will be discussed further in 
Chapters 3 and 4. Eventually the pharmacophore model can be useful to help identify 
other potential ligands if the ligands have a close fit to the model with the appropriate 
binding groups.  
When beginning the pharmacophore identification process, one should determine 
the appropriate calculation levels to be used to minimize the energy (at the equilibrium 
geometry) for each molecule. More sophisticated methods include density functional and 
ab initio optimizations; both are used in this study. 
 QSAR (Quantitative Structure-Activity Relationship) models, particularly 3D 
methods, consider properties of a molecule as opposed to individual substituents or 
moieties, typically utilizing software and hardware to achieve this; the premise is based 
on the assumption that the most important features about a molecule are its size, shape 
and electrostatic properties  (Patrick, 2005). There are several approaches to QSAR but 
the common one is CoMFA which is used in this study based on the assumption that the 
ligand-receptor interactions are non-covalent and that biological activity correlate with 
the changes in the steric and/or electrostatic fields of the drug molecules (Patrick, 2005).  
 The first steps in CoMFA include the aforementioned determination of the active 
conformations and consequently pharmacophore identification. The next step is to place 
the pharmacophore into a lattice where it will act as a reference when positioning other 





(Patrick, 2005).  The steric and electrostatic fields around each molecule are measured. 
The measurements are conducted by putting a probe atom (i.e. carbocation) and 
determining the attraction or repulsion between the probe and the molecule at each of the 
lattice points, consequently calculating steric, electrostatic and hydrophobic interaction 
energies shown through countour lines (Patrick, 2005). The CoMFA is not complete until 
statistical procedures are followed to validate the measurements to determine the 
prediction accuracy for biological activity (Martin and Lin, 1996; Patrick, 2005).  
 
2.2.1 Partial Least Squares 
 
Validation techniques are an important aspect of research. Particularly in this study, as 
with most research studies utilizing CoMFA or QSAR techniques, PLS (partial least 
squares) needs to be incorporated through cross-validation. The concept of cross-
validation essentially means that one or more active ligands are left out during the 
process of the computer deriving an equation or relationship, in this case for biological 
activity; this is often referred to as the “leave-one-out” process (Martin and Lin, 1996). 
The resulting equation is then applied to predict the activity for the omitted ligand(s). 
When this process is complete, a final formula is obtained. The predictability of the final 
formula is represented by the cross-validated correlation coefficient, PRESS (Predictive 
Residual Sum of Squares), r
2
, which is often referred to as q
2
 (Leach, 1996; Patrick, 




 as he or she typically would with common regression 
analysis; the higher the r
2
 (closer to 1.0) the better the prediction. Therefore, the q
2
 value 







2.2.2 Criteria for “Robust” CoMFA Models 
Molecular alignment plays a decisive role in CoMFA analysis, since the relative 
interaction energies depend strongly on relative molecular positions; CoMFA then uses 
statistical techniques for correlating several molecular features, such as steric and 
electrostatic properties with their biological activities (Zhang et al., 2011).  As mentioned 
in Section 2.2.1, the “leave-one-out” process concerns cross-validation for the set of data 
presented, essentially verifying what is often referred to as the “training set.”  The 
predictive q
2
 value refers to the internal robustness of the model (Zhang et al., 2011). 
There is an understood minimum value for the q
2
 value of 0.3 to deem a QSAR model as 
statistically significant (Jung et al., 2004; Park et al., 2009). In fact, Clark and Cramer 
presented findings that virtually any q
2
 value greater than 0.25 from CoMFA can be 
accepted as very unlikely to have resulted from chance correlation; however there is 
some possibility that CoMFA and similar PLS-based approaches can overlook a “true” 
correlation within a set of data (1993). With the interest of establishing criteria for robust 
QSAR models, Tropsha and coworkers introduced a new validation criterion (Zhang et 
al., 2011). Many authors consider high q
2
 (for instance, q
2
 > 0.5) as an indicator or even 
as the ultimate proof that the model is highly predictive; however, the high q
2
 does not 
imply automatically a high predictive ability of the model (Golbraikh and Tropsha, 
2002). Golbraikh and Tropsha state that the use of an external set of compounds with 
known experimental data, often referred to as the “test set,” for the model validation is 
always necessary (2002). Further, the aforementioned validation criterion that was 
developed by Golbraikh and colleagues is centered on test set criterion (Golbraikh et al., 



































 is the quantity characterizing linear regression (trendline) between the 
predicted and observed activities while R0
2  is the quantity characterizing linear regression 
with the Y-intercept set to zero (k represents the slope of that line as in Y = kX;  R0
′2 is 
the same as R0
2  but is related to observed vs predicted activities. k′ is the slope of Y = kx 
for R0
′2) (Golbraikh et al., 2003).  Additionally, Golbraikh and colleagues determined that 







2.3 Design of New Ligands 
The development of pharmacophore models, CoMFA analysis, validation techniques and 
collected observations about the molecular properties, all aforementioned, combine to 
yield the design of new ligands with prediction of activities.  CoMFA contour maps are 
the key to understanding where the enhancement of electrostatic or steric properties 
would benefit a molecule. Therefore, we can see the value in performing this research – 
to eventually design new potential drug candidates for receptors, in this case for sigma 1 




















MOLECULAR MODELING OF SIGMA 1 RECEPTOR LIGANDS 
 
3.1 Introduction 
Sigma receptors were originally and incorrectly characterized as a new subtype of opoid 
receptors in the 1970s (Collina et al., 2007; Marriott et al., 2012). It has been clarified 
that sigma receptors are different from opioid and N-methyl-D-aspartate (NMDA) 
phenycyclidine receptors, that they bind numerous xenobiotics of unrelated compound 
classes including clinical drugs used in psychiatric disorders, neurodegenerative 
disorders, pain, amnesia and abuse drugs such as cocaine (Marriott et al., 2012).  Ligand 
binding experiments and biochemical analysis has differentiated the sigma 1 receptor 
from sigma 2 receptor (Rack et al., 2011). The sigma 1 receptor has been cloned and is a 
25.3 kDa membrane bound protein; the amino acid sequence does not show any 
homology or similarity with any other known mammalian protein (Hanner et al., 1996, 
Rack et al., 2011). Sigma 2 receptors are understood to be smaller in size than the sigma 
1 receptor and that they do not translocate as the sigma 1 receptor does (Marriott et al., 
2012). There appears to be less information and knowledge of the sigma 2 receptor, 
however its molecular weight has been approximated to be 21.5 kDa (Jasper et al., 2012).  
Concerning the prominence of sigma 1 receptors, large amounts have been discovered in 
various organs and tissues including the heart, liver, kidney and the eye including some 
human tumor cell lines (Rack et al., 2011). The physiological function is still to be 
completely understood beyond calcium channels and neurotransmitter modulation; there 





anagonist/antagonist (Cobos et al., 2008; Collina et al., 2007).  
 In the present study, several classes of sigma 1 ligands were selected. It was 
desired to create a pharmacophore model for each class, compare the models, develop a 
comprehensive pharmacophore that represents all of the selected sigma 1 classes and then 
compare the comprehensive model with the findings previously determined by Gund and 
colleagues. Additional analysis to include comparison to other models by researchers was 
also pursued.  
Gund and colleagues have developed several pharmacophore models through 
various studies. The model developed in 1991 by Gund was originally compared with the 
initial idea of Manallack and coworkers regarding hydrophobic and hydrophilic sites 
(Gund et al., 1991; Jung et al., 2004; Manallack et al., 1988). The model in 1991 had 
corresponding distances of 5.3-5.7 angstroms for N-C, 7.3-7.9 angstroms for C-lone pair 
and 2.7-3.0 for N or C – lone pair (Gund et al., 1991). This model was further developed 
by Jung, Floyd and Gund in 2004 with values for those distances, respectively, of 7.138, 
8.662 and 2.508 angstroms. Note that Figure 3.2 presents that an additional 
electronegative feature, the oxygen, as a feature of the pharmacophore model at that time.  
 
 
Figure 3.1 Gund pharmacophore for sigma 1 receptor ligands. 








Figure 3.2 Gund pharmacophore for sigma 1 receptor ligands. 




 This study builds on the original Gund models from 1991 and 2003. The other 
models, which vary from researcher to researcher, are explored and compared with the 




3.2 Selection of Ligands 
Fourty-four sigma 1 receptor ligands were selected for the present study – concerning 
sigma 1 - based on an extensive literature search. Considerations for selection included 
incorporating recently synthesized and researched ligands (from 2012 and 2013) that 
showed properties of moderate to high affinity values calculated via competitive 
radioligand binding studies using [
3
H](+)(-)pentazocine as a radioligand. Highly active 
ligands previously studied by Gund and colleagues were also included as references.  
Tacke and coworkers focused on a series of high-affinity, selective sigma ligands 
of 1,2,3,4-tetrahydrospiro[naphthalene-1,4’piperidine] type along with related sigma 
ligands of the 1,4’-silaspiro[indane-1,4’-piperidine] type (Tacke et al., 2012). Note that 
silasubstitution was a key aspect of Tacke’s study to determine the effect of replacing the 





in these series are presented with their affinity data in Tables 3.1 and 3.2 for compounds 
1-8. 
Table 3.1 Binding and Functional Data of 1,2,3,4-tetrahydrospiro[naphthalene-1,4’-




Compound R1 group  σ1Ki(nM) σ2Ki(nM) σ2/ σ1 
 
1*      2.0 ± 0.5 44 ± 21 22 
 
2    3.8 ± 1.8 206 ± 71 54 
 
3    8.0 ± 1.9 34 ± 4.7 4 
 
4    1.8 ± 1.3 5.5 ± 1.5 3 
 
*Indicates included in the comprehensive sigma 1 pharmacophore derivation. 












Compound R1 group  σ1Ki(nM) σ2Ki(nM) σ2/ σ1 
 
5      1.1 ± 0.5 243 ± 94 221 
 
6    2.7 ± 0.5 460 ± 96 170 
 
  
7    2.9 ± 0.8 39 ± 11.8 13 
 
8    0.3 ± 0.2 19 ± 1.4 63 
 




For compounds 9-14, Harel and colleagues combined the pharmacophoric 
elements of potent sigma 1 ligands spirocyclic thienopyrans to result in aminoethyl 
substituted tetrahydrobenzothiophenes (Harel et al., 2013). Though the resulting 
molecules demonstrated a reduction in affinity (moderate to low), modeling this class, 
particularly by overlaying the molecules, can teach us visually how closely the new 





Further, we can learn from the work of Harel and coworkers that essentially increasing 
the conformational flexibility of the aminoethyl side chain can explain the decrease in 
affinity in this class (Harel, et al., 2013). These molecules and corresponding data are 
shown in Tables 3.3 and 3.4. 
 
 
Table 3.3 Binding and Functional Data of Spirocyclic Thienopyran System and  







Compound R1 group  σ1Ki(nM)  σ2Ki(nM)  σ2/ σ1 
 
9*  CH2Ph   0.31 ± 0.06  13 ± 2.5  42 
 
10  CH2C6H11  0.66 ± 0.16  3.3 ± 0.3  5 
 
*Indicates included in the comprehensive sigma 1 pharmacophore derivation. 
















Table 3.4 Binding and Functional Data of Spirocyclic Thienopyran System and  






Compound R1 group  σ1Ki(nM) σ2Ki(nM)   σ2/ σ1 
 
11  PhCH2   49 ± 2.0 149     3 
 
12  PhCH2CH2  126 ± 73 129 ± 20   1 
 
  
13  PhCH2CH2CH2 132  166    1 
 
14  C6H11CH2  5.0 ± 2.0 10 ± 1.0   2 
 




Compounds 15-17 were studied by Wang and colleagues (2013) to evaluate 
potential radiotracers for imaging sigma 1 receptors with PET (Positron Emission 
Topography). Interestingly, the lead compound, 1-(1,3-benzodioxol-5-ylmethyl)-4-94-92-
fluoroethoxy)benzyl)piperazine) does not exhibit the highest activity compared to other 
compounds in this study (activity at 1.85 nM but comparable with references), however it 
has been identified as a suitable radiotracer and therefore is worth studying as it does 
have an impact for sigma-1 receptor-type applications (Wang et al., 2013). Compounds 





benzylpiperazine derivatives as potential sigma 1 receptor ligands. These molecules and 
corresponding data are shown in Table 3.5  
 






Compound R1 group   σ1Ki(nM) σ2Ki(nM) σ2/ σ1 
 
15* F    1.85 ± 1.59 291 ±111 157 
 
16  OCH2CH2F   40.7 ± 22.8 666 ± 106 16.4 
 
  
17      OCH2CH2OCH2CH2F  505 ± 120 1420 ± 160 2.81 
 
*Indicates included in the comprehensive sigma 1 pharmacophore derivation. 
Source: Wang et al., 2013. 
 
 
 Compounds 18-38, spirocyclic thophenes, were studied by Meyer and coworkers 
(2012). This group studied pharmacophore models from various papers for sigma 1 and 
consequently tried to enlarge the lipophilic region of the thiophene moiety to achieve a 
higher sigma 1 affinity (Meyer et al., 2012). The sigma 1 affinity of the phenylated 
compounds is comparable or slightly reduced compared to the nonphenylated 
compounds; the placement of the S-atom appears to be a key aspect impacting affinity in 
this study, not necessarily increasing the lipophilicity of the thiophene moiety (Meyer et 





to the focus of the impact of structural changes on the binding sites they are worth 
studying; the corresponding data and molecules are in Table 3.6. 
Table 3.6 Binding and Functional Data of Spirocyclic Thiophenes Series  
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Table 3.6 (continued) Binding and Functional Data of Spirocyclic Thiophenes Series  
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Table 3.6 (continued) Binding and Functional Data of Spirocyclic Thiophenes Series  
 
 
Compound    σ1Ki(nM)  
 
18     1.0 ± 0.30
 
19     1.9 ± 0.44 
 
  
20        255 
 
21     0.35 ± 0.06 
 
22     0.22 ± 0.06
 
23     40 ± 13 
 
  
24        0.32 ± 0.10
 
25     1.6 ± 0.70 
 
26     5.4 ± 0.97
 
27     5.3 ± 0.88 
 
  
28        2.4 ± 0.69
 
29     16 ± 5.8 
 
30     23 ± 9.9 
 
31     4.5 ± 2.9 
 
32     1.0 ± 0.4
 
33     2.5 ± 0.91 
 
  
34        5.5 ± 1.5
 
35     16 ± 6.8 
 
36     11 ± 3.2 
 
  
37        483 
 
38     87 ± 52 
 






Since we are building on the foundation of Gund and colleagues, it is appropriate 
to use reference compounds from their work (Gund et al., 2004). Commonly researchers 
use rigid compounds for the pharmacophore modeling to help serve as templates since 
the rotatable bonds are more limited, reducing the number of potential conformers. In the 
selection of reference compounds, some rigid molecules were considered such as 
Spipethiane (43) and (+)-Pentazocine  (44). An extremely highly active compound for 
sigma 1, PD144418 (41) is also included, however it has many conformers/rotatable 
bonds. The reference molecules included from Gund’s previous work are in Table 3.7. 
 
Table 3.7 Binding and Functional Data of Reference Compounds  
    
 
39 (+)3PPP    40  Haloperidol 
 













Table 3.7 (continued) Binding and Functional Data of reference compounds  
   
41  PD144418     42  PRE084 
 
 
   




Compound  σ1Ki(nM) σ2Ki(nM) σ1/ σ2   
 
39   23.7 ± 3.8 176.3 ± 23 7             (Jbilo et. al, 1997)
 
40   1.2 ± 0.20 26 ± 5.4 22  (Akunne et. al, 1997) 
 
  
41*  0.08  1377  5.8 × 10
-5 
(Akunne et. al, 1997) 
 
42   44      (Su et. al, 1991) 
 
43*  0.5 ± 0.02 416 ± 43 0.0012  (Quaglia et al., 1998) 
 
44*  5.8 ± 1.0 1253 ± 519 0.0046  (Akunne et. al, 1997) 
 
*Indicates included in the comprehensive sigma 1 pharmacophore derivation. 









3.3 Materials and Methods 
All molecules were initially drawn in Spartan ’14 and then optimized at the HF/6-31G* 
and B3LYP/6-31G* levels prior to being imported into the SYBYL-X 2.1 program. 
Molecular databases were created within SYBYL-X 2.1 to represent each class of 
compounds for the sigma 1 receptor ligands. DISCOtech, a tool within SYBYL-X 2.1, 
was then used to generate pharmacophores for each of the classes. Pharmacophore 
development for each set of selected molecules was conducted by utilizing the options 
within DISCOtech for feature selection (binding site), conformer searches, etc. to yield 
potential pharmacophore models. Following the development of pharmacophore models 
for each class, a database was created to include the most active/lead compounds with 
some rigid references and active references from the previous work by Gund and 
colleagues. This database was then utilized to develop a  comprehensive pharmacophore 
to represent all of the sigma 1 ligand classes studied in this work. Once pharmacophore 
models were completed, the Comparative Molecular Field Analysis models were created 
for the sigma 1 molecules calculated at HF/6-31G* and B3LYP/6-31G* levels, 
respectively. New ligands were designed once the CoMFA models were determined to 
meet robust criteria; contour maps generated from the CoMFA models were studied 
during the new ligand design process. Additional information about the pharmacophore 









3.4 Pharmacophore Derivation 
DISCOtech allows the researcher to manually select the binding features of each 
molecule to be considered for pharmacophore generation. For these classes, hydrophobic 
groups, positive nitrogen, lone pair and aromatic groups (same as the hydrophobic groups 
selected in these particular cases) were used. This was done via an iterative process. First, 
models were explored without constraints or features selected, and gradually various 
combinations of binding groups were included;  eventually this iterative process yielded 
the typical models, in terms of binding sites, that Gund and coworkers had developed 
over the years (Jung et. al, 2004).   Specifics regarding each class and the derivations are 
discussed in Section 3.4.1.  
 
3.4.1 Pharmacophore Models 
Pharmacophores were generated using DISCOtech in SYBYL-X 2.1 for each class of 
compounds and are shown as labelled in Figures 3.3 through 3.16 and Figures 3.19 
through 3.21. As with the aforementioned Gund, Jung, Floyd models discussed (2003, 
2004), the main binding sites are the nitrogen site, the lone pair of electrons and a 
hydrophobic/aromatic group. The distances between these groups for the various classes 
are on the order of the previous models which are in Figures 3.1 and 3.2; these models 
are more extensively analyzed during the discussion later in this section concerning the 
representative sigma 1 pharmacophore (Figures 3.19 – 3.21).  
 Figures 3.3 – 3.5 depict the model developed for the Tacke Series: 1,2,3,4-
tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine] 





the center of the aromatic/hydrophobic ring (phenyl) to the N atom the distance was 5.08 
Å; and the distance from the lone pair to the center of the aromatic/hydrophobic ring was 
6.89 Å.  
 
Figure 3.3 DISCOtech pharmacophore derivation and overlay of 1,2,3,4-
tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine] 
series (compounds 1-8, hydrogen atoms hidden).  
 
 
Figure 3.4 DISCOtech pharmacophore derivation of 1,2,3,4-
tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine] 






Figure 3.5 DISCOtech pharmacophore model of 1,2,3,4-tetrahydrospiro[naphthalene-
1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine] series (compounds 1-8). Purple 
sphere = acceptor site, red sphere = positive nitrogen and green sphere = 
aromatic/hydrophobic center. 
 
Figures 3.6 – 3.8 depict the pharmacophore derivation of the spirocyclic thienopyran 
system and  aminoethyl-substituted tetrahydrobenzothiophenes (compounds 9-14). Note 
that in this case, the aromatic/hydrophobic ring consists of a thiophene ring. The distance 
from the N atom to the lone pair was 2.9 Å; from the center of the aromatic/hydrophobic 
ring to the N atom the distance was 5.53 Å; and the distance from the lone pair to the 






Figure 3.6 DISCOtech pharmacophore derivation of spirocyclic thienopyran system and  




Figure 3.7 DISCOtech pharmacophore derivation of spirocyclic thienopyran system and  
aminoethyl-substituted tetrahydrobenzothiophenes (compounds 9-14) with lead 









Figure 3.8 DISCOtech pharmacophore model of spirocyclic thienopyran system and  
aminoethyl-substituted tetrahydrobenzothiophenes (compounds 9-14). Purple sphere = 
acceptor site, red sphere = positive nitrogen and green sphere = aromatic/hydrophobic 
center. 
 
Figures 3.9 – 3.11 depict the pharmacophore derivation of the fluoro-oligo-
ethoxylated 4-benzylpiperazine derivatives (compounds 15-17).  Note that in this case, 
the aromatic/hydrophobic ring consists of a phenyl ring. The distance from the N atom to 
the lone pair was 2.9 Å; from the center of the aromatic/hydrophobic ring to the N atom 
the distance was 5.91 Å; and the distance from the lone pair to the center of the 








Figure 3.9  DISCOtech pharmacophore derivation of fluoro-oligo-ethoxylated 4-
benzylpiperazine derivatives (compounds 15-17, hydrogen atoms hidden). 
 
 
Figure 3.10 DISCOtech pharmacophore derivation of fluoro-oligo-ethoxylated 4-







Figure 3.11 DISCOtech pharmacophore model of fluoro-oligo-ethoxylated 4-
benzylpiperazine derivatives (compounds 15-17). Purple sphere = acceptor site, pink 
sphere = positive nitrogen and yellow sphere = aromatic/hydrophobic center. 
 
 
The model for the spirocyclic thiophenes (Figures 3.12 – 3.14) shows a distance 
that is noticeably lower between the nitrogen and hydrophobic group as contrasted with 
other class pharmacophore models; this could be due to difficulty experienced by the 
researcher in directing DISCOtech to consider using the lipophilic groups Meyer and 
coworkers discussed (2012). Poor overlay can be visually observed of the thiophene 
moieties for the 21 spirocyclic thiophene molecules in Figure 3.12.  The distance from 
the N atom to the lone pair was 2.9 Å; from the center of the aromatic/hydrophobic ring 
(phenyl) to the N atom the distance was 3.83 Å; and the distance from the lone pair to the 
center of the aromatic/hydrophobic ring (phenyl) was 6.46 Å.  It is important to note that 
compound 22 from this class was used in the representative pharmacophore for sigma 1, 
and in that pharmacophore the thiophene moiety was used by DISCOtech as opposed to 





alternate pharmacophore model was explored for this class as shown in Figures 3.15 and 
3.16, where the seven most highly active spirocyclic thiophene compounds were chosen 
for the model (compounds 18, 19, 21, 22, 24, 25 and 32). This was a more inclusive 
model depicting additional hydrophobic groups with the objective to confirm that the 
thiophene moiety was a viable hydrophobic group for the pharmacophore as it occurred 
in the representative pharmacophore for sigma 1. Indeed, as shown in Figure 3.16, a 
pharmacophore model consisting of more than three points is possible for this class, and 
the highlighted section with the thiophene moiety, in this case for the most highly active 
ligand – compound 22  –  is presented. In that case, the distance from the N atom to the 
lone pair was 2.9 Å; from the center of the thiophene ring to the N atom the distance was 
5.36 Å; and the distance from the lone pair to the center of the thiophene ring was 7.54 Å. 
Therefore, it was determined that the spirocyclic thiophene class, depending on the 
ligands chosen, could have additional hydrophobic groups as part of the model. When the 
molecules were aligned with other molecules from other classes in CoMFA or used in the 
representative pharmacophore, it was interesting to note that the thiophene moiety 
aligned to the hydrophobic groups of the other molecules as opposed to the original 
phenyl ring used in DISCOtech for the spirocyclic thiophene specific pharmacophore. 
The features of the other molecules later used for the representative pharmacophore were 
a key reason that the approach on the part of the researcher for this study did not include 
other pharmacophoric features that other groups, such as Meyer coworkers, did in their 
2012 work.  Meyer and coworkers similarly used hydrophobic/aromatic points as well as 
the nitrogen atom, however they included additional hydrophobic centers in their 





molecule in this study or theirs (the additional phenyl ring attached to the thiophene ring, 
for instance) and also used donor atoms and corresponding acceptor sites outside of 
nitrogen and its lone pair, which again, did not always exist for the other sigma 1 ligands 
in our study (Meyer et al., 2012). Since the researcher in this study was aiming to develop 
consistency in the class pharmacophores with an overall, representative pharmacophore 
for sigma 1, features as seen in Figures 3.17 and 3.18 were not included. Work continues, 
as stated by Gund et al., in accordance with the suggestion that one pharmacophore may 
be sufficient to rationalize the binding of all sigma ligands (1992).  
There seems to be agreement about the thiophene moiety being a viable binding 
group point as well as the nitrogen atom with the additional possibility of the phenyl 
group nearest the nitrogen atom being a hydrophobic/aromatic point; therefore these three 
points from our Figure 3.16 agree with the Meyer model depicted in Figure 3.17. Again, 
these models are more specific to spirocyclic thiophenes and are not necessarily 
representative to the overall sigma 1 pharmacophore; the “triangle” effect does exist in 
both the original and alternate spirocyclic thiopehene pharmacophores in Figures 3.14 or 
Figure 3.16, with the difference in the hydrophobic/aromatic group being either the 
phenyl ring or thiophene ring, respectively. A final point on the Meyer and coworkers’ 
model is that a different approach and software was used for their pharmacophore 
modeling with the primary focus being spirocyclic thiophenes, specifically to explore the 







Figure 3.12 DISCOtech pharmacophore derivation of spirocyclic thiophenes 








Figure 3.13 DISCOtech pharmacophore derivation of spirocyclic thiophenes 
(compounds 18-38, hydrogen atoms hidden)  with lead compound 18. 
 
 
Figure 3.14 DISCOtech pharmacophore derivation of spirocyclic thiophenes 
(compounds 18-38). Purple sphere = acceptor site, red sphere = positive nitrogen and 









Figure 3.15 Alternate DISCOtech pharmacophore derivation of spirocyclic thiophenes 
(highest activity compounds of series; hydrogen atoms hidden - compounds 18, 19, 21, 
22, 24, 25 and 32).  
 
 
Figure 3.16 Alternate DISCOtech pharmacophore derivation of spirocyclic thiophenes 
with compound 22, hydrogen atoms hidden. Purple sphere = acceptor site, red sphere = 
positive nitrogen and green sphere = aromatic/hydrophobic center. Additional sphere in 








Figure 3.17 Meyer and coworkers’ mapping of compound “3b” (compound 32) onto a 
3D pharmacophore model. Red sphere is the nitrogen/positive ionizable group, pink 
sphere is hydrogen/aromatic group and hydrogen bond acceptor is light green denoted as 
two spheres, the smaller being the location of the hydrogen bond acceptor on the ligand 
and the larger one being the location of the hydrogen bond donor on the receptor.  





Figure 3.18 Distances for spirocyclic thiophene pharmacophore generated by Meyer 
and coworkers. Red sphere = nitrogen, pink sphere = hydrogen/aromatic group and 
hydrogen bond acceptor is light green denoted as two spheres, the smaller being the 
location of the hydrogen bond acceptor on the ligand and the larger one being the 
location of the hydrogen bond donor on the receptor). 
Source: Meyer et al.,  2012.   
 
For the derivation of the sigma 1 representative pharmacophore as depicted in 
Figures 3.19 – 3.21, seven highly active ligands were used. Reference compounds from 
previous work in the Gund group included compound 43, Spipethiane (rigid), compound 





identified). The molecules additionally chosen from the new classes studied in this work 
for the representative pharmacophore included: compound 1 (lead compound for 1,2,3,4-
tetrahydrospiro[naphthalene-1,4’-piperidine] and 1,4’-silaspiro[indane-1,4’-piperidine] 
series), compound 9 (lead compound for spirocyclic thienopyran system and  aminoethyl-
substituted tetrahydrobenzothiophenes), compound 15 (lead compound for fluoro-oligo-
ethoxylated 4-benzylpiperazine derivatives) and compound 22 (highest activity 
spirocyclic thiophene molecule in this study). Spipethiane (compound 43)  was 
designated  as the reference molecule in DISCOtech since it was a rigid yet second 
highest active sigma 1 ligand of the compounds chosen. The resulting pharmacophore 
included the typical features aforementioned – the lone pair of electrons, the nitrogen 
atom and the center of a hydrophobic/aromatic ring. The distance from the N atom to the 
lone pair was 2.9 Å; from the center of the hydrophobic ring (varied from phenyl ring to 
thiophene ring depending on the molecule) to the N atom the distance was 6.80 Å; and 
the distance from the lone pair to the center of the thiophene ring was 8.45  Å. The last 
sigma 1 model from the Gund group in 2003 had proposed the pharmacophore to have 
similar distances for the same binding features. Therefore, the current model shows 8.45 
Å vs 8.662 Å (previous model) for C-lone pair; 6.80 Å vs 7.135 Å (previous model) and 
2.90 Å vs 2.508 Å (previous model) (Jung et al., 2004). The previous model in 2004 had 
used three main classes in addition to references. The three main classes were 
Spipethiane and its analogs, Piperidine and Piperazine Analogs and Benzothiazolone 
Analogs along with other ligands including PD144418 (Jung et al., 2004). The 
importance of the current work is that it essentially takes elements of the work in 1991 






piperidine] series, spirocyclic thienopyran system and  aminoethyl-substituted 
tetrahydrobenzothiophenes and spirocyclic thiophene. The current model therefore 
continues to promote the idea of the original 1991 model of the “triangle” shaped 
pharmacophore, retaining the idea of the importance of the lone pair as an aspect of the 
model; the oxygen atom, though an element in some of the molecules studied and 
previously presented as an important aspect of previous pharmacophore models, is not 
part of the pharmacophore model created in this current study.  
  
 
Figure 3.19 Comprehensive DISCOtech pharmacophore derivation representing entire 
Sigma 1 class of molecules studied (hydrogen atoms hidden – compounds 1, 9, 15, 22, 









Figure 3.20 Comprehensive DISCOtech pharmacophore derivation for Sigma 1. Purple 




Certainly there is consistency, particularly with the aforementioned “triangle” 
shape in terms of distances and the main binding groups of the lone pair, nitrogen atom 
and center of a hydrophobic ring, in the pharmacophore modeling by the Gund group as 
the classes of sigma 1 compounds increased significantly over the years. Other 
researchers have proposed pharmacophore models as well for sigma 1 ligands; most of 
the other models developed have been designed by researchers who have synthesized 
sigma 1 ligands and therefore want to understand the relationship of the activities 
generated with the molecular structure of the synthesized molecules. Laggner and 
coworkers presented their pharmacophore model in Figure 3.22 featuring nitrogen and 
the phenyl group as important binding sites, however the additional hydrophobic groups 
featured are not in agreement in our model (2005). Though the additional hydrophobic 





feature that Laggner’s model does not have – that of the lone pair of electrons as seen in 
Figure 3.21. Note that the researcher did change the feature selection in DISCOtech in 
this study to simulate some of the other models for comparison and educational purposes. 
For instance, DISCOtech could not simulate Laggner’s model because the representative 
sigma 1 ligands did not all have 4 hydrophobic features available, demonstrating that 
pharmacophore models can be very dependent on the molecules chosen. Instead, a 
modified version of Laggner’s pharmacophore was created while including the additional 
feature of the lone pair of electrons as seen in Figure 3.24, however this model is not the 
leading or preferred model of the researcher since it does not represent the alignment 
approach later used for the Comparative Molecular Field Analysis (ComFA). The 
CoMFA, described in detail in Section 3.5, had the tightest alignment by approaching a 
fit primarily around the nitrogen atom and surrounding atoms  (in an attempt to overlay 
the acceptor site and the N atoms of all of the molecules) while simultaneously trying to 
overlay the thiophene or phenyl moieties in the same binding site as the pharmacophore 
in Figure 3.19. Note that most other researchers do not show diagrams of how their 
molecules overlay; though supplemental data is available to address tolerances and 
distances for the binding groups, visually one cannot observe how the cyclohexyl (or N 
and surrounding atoms) align, specifically directionally. Our CoMFA and pharmacophore 
models align directionally for the cyclohexyl ring, with the objective for the lone pairs to 
overlap. Since the CoMFA models conducted in Section 3.5 are considered “robust” and 
highly predictive based on peer-reviewed journal criteria, the researcher for this study 
therefore postulates that the representative pharmacophore in Figure 3.19 is a key 





for the successful CoMFA models.  
Figure 3.23 depicts another pharmacophore model, in this case by Collina et al. 
(2007). Similar to Laggner’s model in Figure 3.22, this model is depicting nitrogen as a 
positive ionizable feature with the remaining three features being hydrophobic binding 
sites.  
For completeness, additional DISCOtech iterations were considered to include 
additional hydrophobic groups since other researchers included them. The model that is 
most similar to our lead pharmacophore from Figure 3.19 is in Figure 3.25 where an 
additional hydrophobic group (near the aromatic/primary hydrophobic groups as 
postulated by other researchers) is shown. This model, however, does not visually appear 
to align as closely for the thiophene/phenyl rings for the aromatic/hydrophobic binding 
site.  
Literature often cites the Glennon model shown in Figure 3.23 (2005). This model 
was recreated in DISCOtech as seen in Figure 3.27 with similar distances; the N atom to 
the primary hydrophobic region being 6.8 Å, consistent with the Glennon range of 6-10 Å 
as well as the N to secondary hydrophobic region being 3.72 Å, consistent with the 
Glennon range of 2.5-3.9 Å. Glennon is another researcher who does not include the 
concept of the lone pair of electrons in his model. If the model is forced to include it, as 
shown in Figure 3.28, the distances between the primary hydrophobic region and the N 







Figure 3.21 Comprehensive DISCOtech pharmacophore derivation with reference 




Figure 3.22 Sigma 1 pharmacophore model for Laggner and coworkers. 









Figure 3.23 Pharmacophore model for Collina and coworkers. Molecules 2 and 12 were 
newly designed and synthesized in arylalkyl and alkenylamines series. Red sphere is 
nitrogen/positive ionizable feature while the cyan spheres are hydrophobic features. 





Figure 3.24 Alternate sigma 1 pharmacophore model with additional hydrophobic groups 
(green spheres) to compare with Laggner et al. model. Pink sphere is N atom and purple 








Figure 3.25 Additional alternate sigma 1 pharmacophore model with additional 
hydrophobic group (green sphere) to compare with Laggner et al. model. Pink sphere is N 







Figure 3.26 Sigma 1 pharmacophore model for Glennon. 







Figure 3.27 Additional alternate sigma 1 pharmacophore model without lone pair of 
electrons to compare with the Glennon model. Pink sphere is N atom and green spheres 
are hydrophobic groups  
 
 
Figure 3.28 Additional alternate sigma 1 pharmacophore model with lone pair of 
electrons to compare with Glennon model. Pink sphere is N atom and green spheres are 
hydrophobic groups Lone pair is included as purple sphere. 
 
 The last pharmacophore model analyzed in this work was from Caballero et al. 





phenylcyclopropane-1-carboxylate (MAPCC) derivatives, resulting in a pharmacophore 
model as shown as “c” in Figure 3.29. Note the comparison between that model and the 
aforementioned Glennon and Laggner models shown as (a) and (b) in the Figure 3.29, 
respectively (Cabellero et al., 2012).  Cabellero’s model differs from the Gund, Laggner 
and Glennon models due to additional acceptor sites; this can mainly be attributed to the 
fact that the structure is unique, particularly with the additional O atoms. The visual 
molecule overlay for their pharmacophore was presented in their paper as well, however, 
these molecules only had minor differences in terms of substituents and therefore the 
conformations in their GALAHAD pharmacophore model molecules did not appear to 
alter much as can be observed visually in Figure 3.30. Therefore, the researcher for this 
study assumed that this pharmacophore is very specific for the MAPCC derivatives class 







Figure 3.29 Caballero and coworkers’ figure depicting comparisons between Glennon 
(a),  Laggner (b)  and their work (c). H1 and H2 are hydrophobic groups. N1 is Nitrogen. 
A1, A2 and A3 are all acceptor groups.  
Source: Caballero et al., 2012. 
 
 
Figure 3.30 Caballero and coworkers’ GALAHAD pharmacophore model of MAPCC 
derivatives and molecular alignment of the compounds. Cyan spheres are hydrophobic 
points; red is positive nitrogen and green spheres are acceptor points. 
Source: Caballero et al., 2012. 
 
 
 In summary, pharmacophore models were derived by the researcher for the 
classes studied in this work. Additionally a representative pharmacophore was designed 
and applied in the alignment techniques discussed in the CoMFA in Section 3.5. Again, 
due to the success of the CoMFA using the pharmacophore in Figure 3.19 (which focuses 
on the lone pair, hydrophobic/aromatic group and the N atom) and also due to the 
aforementioned differences noted in the molecules and pharmacophore approaches 
chosen by the other researchers, the leading, comprehensive model proposed by this 
study remains to be the postulated model as depicted in Figures 3.19 – 3.21. As an 





representative pharmacophore models for sigma 1 and Spipethiane was consistently 
applied as the template/reference molecule in the alignments for the CoMFA studies in 
Section 3.5. 
 
3.5 Comparative Molecular Field Analysis 
3.5.1 Geometry Optimization and Electrostatic Studies 
Each molecule in this study was optimized and saved at the ab initio HF/6-31G* and 
density functional B3LYP/6-31G* levels with electrostatic charges. Once each molecule 
was optimized, it was saved as a “.mol2” file with “electrostatic” to carry the 





Alignment of the HF/6-31G* and B3LYP/6-31G* optimized geometries for the sigma 1 
ligands was an essential step in generating a CoMFA model for each calculation level, 
respectively. A key point is that this was a rigid alignment approach with the intent to 
maintain the bound conformation of each molecule at the calculation level being studied. 
Many researchers, however, use flexible alignment approaches; as an example, Caballero 
and researchers state that their 3D-QSAR models rely on the arbitrary alignment of 
conformationally flexible ligands (2012).  Since part of the objective of this study was to 
observe the results, comparing ab initio with density functional methods, and also since 





assumption was made that the energy should be minimized. Therefore the ab initio and 
density functional methods calculated energy minimized geometries while also 
calculating the electrostatic charges.  The resulting molecules were then rigidly aligned to 
each other. 
The approach to alignment for the sigma 1 ligands consisted of matching up the N 
atom and surrounding items, particularly those of the cyclohexyl ring, and matching up 
the phenyl/thiophene (hydrophobic ring) moieties with the objective being to bind the 
molecules together at the pharmacophore binding groups as seen in Figures 3.19 – 
Figures 3.21. Spipethiane was the reference molecule used for the pharmacophore model 
and therefore was the template molecule used to drive the alignment process.  Since 28 of 
the molecules in the data set that had similar geometry (cyclohexane ring), they were 
initially matched to Spipethiane as the template using the “DISTILL RIGID” alignment 
tool. The remaining molecules in the various classes were then manually aligned using 
the “match atoms” feature; Spipethiane was first used as the template to match with the 
lead compounds for the remaining series. Then the remaining molecules of those classes 
were aligned to the lead compounds. Finally, the spirocyclic thiophene series was 
removed from the whole database and was manually aligned at the thiphene moieties and 
at the N and surrounding atoms to ensure a tighter alignment; then it was reintroduced 
back to the database. Note that the researcher determined it was appropriate to leave out 
the fluoro-oligo-ethoxylated 4-benzylpiperazine derivatives. Though the most active 
ligand from that series remains in the pharmacophore, the series, perhaps due to 
extremely different geometry/length and very varied activities (1.85 to 505 nM) 





series could perhaps instead be studied separately in the future and should be left out of 
the CoMFA model; this is not uncommon in the area of QSAR, as other researchers have 
similarly left out compounds when approaching rigorous modeling as seen by Dessalew 
and colleagues for aminothiazole derivatives (Dessalew et al., 2007). The resulting 
alignment for the sigma 1 ligands therefore consisted of 41 total sigma 1 molecules from 
all of the other classes and reference molecules described. Consistent with the robust 
criteria described in Section 2.2, 5 molecules were chosen as the test set with the 
remaining 36 molecules acting as the training set. Additional details are provided in 
Section 3.5.3. The final alignment of all 41 molecules can be viewed in Figure 3.31 for 
HF/6-31G* and Figure 3.32 for B3LYP/6-31G*. The resulting alignments led to robust 
models as described in Section 2.2.2. Additional details about the CoMFA models are 








Figure 3.31 Alignment of all 41 sigma 1 ligands at the HF/6-31G* calculation level.  
 







3.5.3 Quantitative Structure Activity Data Analysis 
The CoMFA models were initiated by first conducting the molecular alignment as 
described in Section 3.5.2. Each activity (Ki) value was converted to a pKi value using 
Equation 2.4. The training set for the CoMFA ensured a range of at least 3 log units in 
terms of pKi, as is suggested in the field and demonstrated by other researchers (Bolden 
et al., 2013). The training set ranged from -2.6839 to 1.0969 whereas the test set ranged 
from -1.6021 to 0.1805 log units. The histograms of the pKi vs number of molecules are 
shown in Figures 3.33A and 3.33B. 
 
 







Figure 3.33B Histogram of frequency vs pKi for sigma 1 ligands in test set. 
 
 The CoMFA models were constructed using the default settings in SYBYL-X 2.1. 
Therefore, an sp
3
 hybridized carbon atom was probed with a +1.0 unit charge which 
extended at least 4 Å beyond each molecule, 2.0 Å grid spacing and the default 30 
kcal/mol energy cutoff for steric and electrostatic fields. The CoMFA column, combined 
with the literature pKi values, generated the Partial Least Squares cross-validated q
2
 for 
each set, resulting in a predicted bioactivity (pKi) value for each training set molecule. 
The test set, molecules which were not used to create the model, was used to validate the 
model by comparing predicted bioactivities generated with the experimental results. The 
resulting sigma 1 dataset at HF/6-31G* with 36 molecules in the training set resulted in a 
q
2





resulting sigma 1 dataset at B3LYP/6-31G* with 36 molecules in the training set resulted 
in a q
2 
value of 0.575; the predicted bioactivity values for that set is in Table 3.8. The 






Table 3.8 Experimental and Predicted Bioactivities (pKi) by the Training Set of 
Sigma 1 Compounds using ab initio and Density Functional Calculation Methods 
 
Compounds             Lit. pKi         HF/6-31G*  B3LYP/6-31G*  
 



































































































































































































































































Table 3.9 Experimental and Predicted Bioactivities (pKi) by the Test Set of Five 
Sigma 1 Compounds using ab initio and Density Functional Calculation Methods 
 
Compounds             Lit. pKi         HF/6-31G*  B3LYP/6-31G*  
 





































The Partial Least Squares Analysis (PLS), as described in Section 2.2.1, was used 
by applying the SAMPLS algorithm in SYBYL-X 2.1 developed by Bruce Bush. The 
optimum number of components was determined by the SYBYL-X 2.1 in the output 
report from the SAMPLS algorithm and is shown in bold in Table 3.10. The number of 
optimal components identified in the report was then applied without cross-validation 
yielding the results in Table 3.11. The R
2
 values for HF/6-31G* and B3LYP/6-31G* 
without cross-validation, using the optimal number of components for each, respectively, 
at 5 and 4 yielded 0.959 and 0.938. Note that Table 3.11 also presents the electrostatic 
and steric contributions to the CoMFA field. 
 
Table 3.10  Optimal Component Number and q
2
 by “Leave-One-Out” using SAMPLS 
by the Training Set of 36 Molecules  
 
Lev. Term C. 1 C. 2 C. 3 C. 4 C. 5 C. 6 C. 7 C. 8 C. 9 C. 10 




  0.338 0.438 0.474 0.484 0.505 0.504 0.499 0.499 0.489 0.461 
            B3 s.e.e. 0.713 0.660 0.641 0.642 0.658 0.690 0.701 0.723 0.749 0.763 
  q
2
  0.425 0.522 0.563 0.575 0.568 0.541 0.542 0.530 0.515 0.515 






Table 3.11 QSAR Reports by Non-Crossvalidation Using SAMPLS by the Training 





 F Values Steric. Electro. 
HF/6-31G* 0.203 0.959 (n1 = 5, n2 = 30) 139.468 0.381 0.619 
B3LYP/6-31G* 0.246 0.938 (n1 = 4, n2 = 31) 116.722 0.392 0.608 
s.e.e. is standard error of estimates.  
 
The application of the robust criteria as described in Section 2.2.3 is shown in Figures 
3.34 and 3.35 for HF/6-31G* in the graphs of predicted pKi values vs experimental pKi 
values. The training set and tests were subject to Equations 2.5 – 2.9; those equations 
were used to calculate and confirm that the HF/6-31G* CoMFA model meets the robust 








y = 0.9582x - 0.028 


























Test  set: 
y = 1.2176x + 0.2222 
R² = 0.8893 
 
y = 1.0392x 








Figure 3.35  Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA 
model at HF/6-31G*. 
 
 
Table 3.12A Results for QSAR Robust Criteria Equations 2.5 – 2.9 for HF/6-31G* 
(Sigma 1) 
 
Equations (2.5 – 2.9) Value 
q
2















=  0.05 and 𝑘 = 1.04 
|R0
2 − R0
′2|  < 0.3 |R0
2 − R0
′2| = 0.06 
 
The application of the robust criteria as described in Section 2.2.3 is shown in Figures 
3.36 and 3.37 for B3LYP/6-31G* in the graphs of predicted pKi values vs experimental 
y = 0.8477x 


































pKi values. The training set and tests were subject to Equations 2.5 – 2.9; those equations 
were used to calculate and confirm that the B3LYP/6-31G* CoMFA model meets the 
robust criteria as defined by Golbraikh and colleagues in Table 3.12B (2002, 2003). 
 
 
Figure 3.36  Graph of Predicted pKi vs Experimental pKi by the CoMFA model at 
B3LYP/6-31G*. 
 
y = 0.9383x - 0.0491 




























y = 0.87x - 0.1381 
R² = 0.796 
 
y = 0.9809x 







Figure 3.37  Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA 
model at B3LYP/6-31G*. 
 
 
Table 3.12B Results for QSAR Robust Criteria Equations 2.5 – 2.9 for B3LYP/6-31G* 
(Sigma 1) 
 
Equations (2.5 – 2.9) Value 
q
2















=  0.04 and 𝑘 = 0.981 
|R0
2 − R0
′2|  < 0.3 |R0
2 − R0
′2| = 0.03 
 
In summary, the bioactivity prediction for both models at HF/6-31G* and B3LYP/6-
31G* were considered robust via PLS and the criteria set by Golbraikh and colleagues 
(2002, 2003). Therefore, the model can serve as a means to predict other compounds for 
y = 0.9015x 


































sigma 1 activity.  
 
3.5.4 Contour Maps of CoMFA Models 
Contour maps from the CoMFA models were explored with the objective to understand 
the desired sterics and electrostatics that could enhance the activity of a molecule, 
enabling the design of new ligands. In the maps, green represents steric bulk desirable 
whereas yellow represents steric bulk undesirable. In terms of electrostatics, the maps 
depict red for negative charge desirable whereas blue represents positive charge as 
desirable. The differences observed in the CoMFA contour maps between HF/6-31G* 
and B3LYP/6-31G* were also explored.  
Figure 3.38 and Figure 3.39 show the contour maps for compound 43, 
Spipethiane, which served as the reference molecule for pharmacophore generation as 
well as the template molecule for the CoMFA alignment. Note that the steric bulk 
desirable is consistent for the phenyl ring on the right and the left for both calculation 
levels, however, there is some difference regarding bulk above and below the center of 
the molecule. In terms of electrostatics, negative charge was consistently desirable over 
the left phenyl ring, however positive charge did not display consistently between the two 
















Figure 3.40 and Figure 3.41 show the contour maps for compound 41, PD144418, 
the most active sigma 1 ligand in this study. Similar to the contour maps for Spipethiane, 
the steric bulk desirable is consistent for the phenyl ring on the left for both calculation 
levels; it is also consistent on the right side with the CH2 groups. There is some 
difference regarding bulk above and below the center of the molecule. In terms of 





however, positive charge did not display consistently between the two calculation levels 









Figure 3.41 Contour map of compound 41 (PD144418) at B3LYP/6-31G*.  
 
 
Additional contour maps showing the contour maps of the lead compounds can be found 








3.6  Design of New Sigma 1 Ligands 
 
Utilizing the analysis conducted in Section 3.5.4, the design of new ligands was 
conducted on compound 43, Spipethiane and compound 41, PD144418. The contour 
maps showed that the area over the phenyl ring (left of the area with the S atom as seen 
in Figures 3.38 and 3.39 – considered to be R1) had more bulk desirable, however it 
depicts a slim profile for bulk. It also shows that the same area had negative charge 
desirable. Therefore, various combinations were tried to meet the profile for bulk over 
the phenyl ring while altering the electronegativity. Additionally, the phenyl ring on the 
right side in Figures 3.38 and 3.39 showed a clear bulk desirable area – considered to be 
R2 - and therefore, a tertiary butyl group was also tried for that area. The predicted 
activities are shown in Table 3.13. The highest predicted activity increase consisted of: 
0.2767 to 0.9242 at HF/6-31G* and 0.1636 to 0.7971 at B3LYP/6-31G* (literature 
value at 0.301). Additionally, electronegative groups added in the R1 position such as 
COOH, F and Cl, with H as the R2, improved bioactivity. A tertiary butyl group as the 
R2 with H as the R1 also improved bioactivity. Note that low Ki values are desirable as 
they represent high bioactivity (less compound to create an effect), however when the 
Ki values are converted to pKi values then high pKi values are most desirable as they 
mean high bioactivity (low pKi values represent low activity). The contour maps related 









Table 3.13: Spipethiane-based New Ligands 
 
Compounds      R1           R2          Lit. pKi  HF/6-31G* B3LYP/6-31G*  
 
         Predicted pKi   
  
43       H       H  0.301   0.2767   0.1636 
 
45    H N/A  -0.2077   -0.1841 
 
46    H N/A  -0.0808   -0.2361 
 
47      CH3  H           N/A  -0.0682   -0.1227 
 
48      Cl  H  N/A  0.4989    0.303 
 
     
49   
    H N/A  0.7345   0.6057 
 
50       F  H N/A  0.6274   0.4738 
 
51       I  H N/A  0.2085   0.0463 
 
 
52               tbutyl N/A  0.9242   0.7971 
 
 












In Figures 3.42 and 3.43 a phenyl ring with a fluorine attached (to help the 
electronegativity) was added as the R1 group. The R1 group overlapped into the yellow 
undesirable area, perhaps the reason the bioactivity did not improve for this case. 
 
 




Figure 3.43 Contour map of compound 45 at B3LYP/6-31G*. 
 
In Figures 3.44 and 3.45 a phenyl ring was added to explore adding bulk as R1 without 
the influence of fluorine; the activity did not improve, perhaps because the R1 group 











Figure 3.45 Contour map of compound 46 at B3LYP/6-31G*. 
 
In Figures 3.46 and 3.47 a methyl group was added as R1 with the intent to better fit the 
desirable bulk profile; even though the methyl group did not overlap into the undesirable 
bulk area of the contour map in the HF/6-31G*, there was no benefit to adding it in terms 





















Figure 3.47 Contour map of compound 47 at B3LYP/6-31G*. 
 
 
In Figures 3.48 and 3.49, chlorine was added as the R1 substituent. The overlap into the 
desirable negative charge area can be observed on the map and perhaps explains the 
improved bioactivity values of 0.4989 and 0.303 (from 0.2767 and 0.1636) at HF/6-31G* 










Figure 3.49 Contour map of compound 48 at B3LYP/6-31G*. 
 
 
In Figures 3.50 and 3.51, COOH was added as the R1 substituent. The overlap into the 
desirable negative charge area can be observed on the map and perhaps explains the 
improved bioactivity values of 0.7345 and 0.6057 (from 0.2767 and 0.1636) at HF/6-















Figure 3.51 Contour map of compound 49 at B3LYP/6-31G*. 
 
 
In Figures 3.52 and 3.53, F was added as the R1 substituent. The overlap into the 
desirable negative charge area can be observed on the map and perhaps explains the 
improved bioactivity values of 0.6274 and 0.4738 (from 0.2767 and 0.1636) at HF/6-












Figure 3.53 Contour map of compound 50 at B3LYP/6-31G*. 
 
 
In Figures 3.54 and 3.55, I was added as the R1 substituent. The bioactivity did not 
















As aforementioned, there was successful minimization with increased activity by adding 
electronegative substituents or groups such as COOH at the R1 spot and adding a tertiary 
butyl (tbutyl) group to the R2 spot. In fact, for Spipethiane, this combination, shown in 
Figures 3.56 and 3.57, resulted in the most highly active new ligand according to both the 
HF/6-31G* and B3LYP/6-31G* CoMFA models at 0.9242 and 0.7971 pKi values, 





converted. This data is useful as it shows that Spipethiane, which is more rigid than the 
most active sigma 1 ligand identified, PD144418 could potentially have close to the same 
activity, where PD144418 currently measures at 0.08 nM. PD144418 as a basis for new 
ligands was also explored to determine if there are possibilities to increase the value of 










Figure 3.57 Contour map of compound 52 at B3LYP/6-31G*. 
 
 
Continuing to apply tbutyl as an R2 group, but without an R1 group (using hydrogen 





models but is not as effective as when having an R1 group such as COOH. Consequently 
the pKi values were 0.4608 and 0.3224 for HF/6-31G* and B3LYP/6-31G*, respectively. 









Figure 3.59 Contour map of compound 53 at B3LYP/6-31G*. 
 
 
The design of new ligands around Spipethiane led to findings mentioned above; 
therefore, design of new ligands also occurred with PD144418, the most highly active 
sigma 1 ligand, to determine if there is the possibility that it could be even more active. 





as F, Cl and COOH can help improve the bioactivity of PD144418 but that the addition 
of bulk, in either R, R1 or R2 (Table 3.14 and Table 3.15), did not help. Part of this could 
be due to the fact that since PD144418 is more flexible than Spipethiane; when the 
molecule would minimize at the calculation levels the substituents would not always 
appear in the expected location from the way it was designed. The highest predicted 
bioactivity consisted of adding COOH on the R position (similar to R1 on Spipethiane 
earlier) to yield a pKi of 1.5842 vs 1.2858 (literature pKi as 1.0969); this could potentially 












Compounds       R            Lit. pKi  HF/6-31G*  B3LYP/6-31G*  
 
         Predicted pKi   
  
41      H  1.0969  1.096   1.2858   
 
54      Cl  N/A  1.0975   1.425  
  
 
55      N/A  0.5144   1.1845  
  
 
56    
(diamantane) N/A  0.1275   0.2823 
 
 
57    N/A  1.0129   1.5842 
 
















Compounds    R1            R2  HF/6-31G*  B3LYP/6-31G*  
 
         Predicted pKi   
  
59                tbutyl  0.6897   1.0166   
 





Figures 3.60 and 3.61 demonstrate a situation where the molecule minimized in a way 
that the Cl added as the R group could not reach the red area of electronegativity 
desirable as well as expected, however the bioactivity did improve, minimally for HF/6-
















Figure 3.61 Contour map of compound 54 at B3LYP/6-31G*. 
 
 
Figures 3.62 and 3.63 demonstrate a situation where the molecule minimized in a way 
that the cyclohexyl with CO added as the R group overlapped to the yellow undesirable 
area. Also the O atom did not overlap into the desirable red electronegative area. 











Figure 3.63 Contour map of compound 55 at B3LYP/6-31G*. 
 
 
In an attempt to overlap the bulk desirable areas of the contour maps in Figures 3.64 and 
3.65, diamantane was added as the R group for compound 56. The bioactivity did not 

















Figure 3.65 Contour map of compound 56 at B3LYP/6-31G*. 
 
 
COOH was added as the R group for Figures 3.66 and 3.67 in compound 57. Though the 
minimization of the molecule appears to present another case where the R group could 
not overlap well with the red desirable electronegative areas, the bioactivity improved for 

















Figure 3.67 Contour map of compound 57 at B3LYP/6-31G*. 
 
 
F was added as the R group for Figures 3.68 and 3.69 in compound 58. In this case the F 
consistently overlapped the red electronegative areas and improved the bioactivity on 
both HF/6-31G* and B3LYP/6-31G* levels at 1.4306 and 1.4538, respectively (vs 1.096 
















Figure 3.69 Contour map of compound 58 at B3LYP/6-31G*. 
 
 
There was an additional combination considered based on the successful results from the 
newly designed ligands based on Spipethiane. Therefore, for Table 3.15, R2 used a 
tertiary butyl group and the consideration of H or COOH was used for R1. The results 
show that there is no improvement in bioactivity even though the tbutyl group overlaps 





minimization of the molecule, the added COOH did not overlap with the red 































Note that there were attempts to add diamantane as an R1 group to explore adding bulk 
further to compound 43, spipethiane (as it was done for PD144418), however the 
resulting molecules did not minimize successfully and were therefore aborted. Similarly, 
adding a cyclohexane ring attached to a C=O group at the R1 location also did not 
minimize successfully for Spipethiane; this particular combination was aimed at 
exploring bulk combined with electronegativity.  





best cases of completed optimizations at both calculation levels with increases in activity 
were due to the addition of electronegative substituents or groups such as fluorine, 
chlorine and COOH. It was also observed that adding the tbutyl group in the R2 position, 
while having an electronegative group such as COOH at R1, for Spipethiane increased 
the activity. Certainly these are promising results, leading to the possibility that the newly 

















MOLECULAR MODELING OF SIGMA 2 RECEPTOR LIGANDS 
 
4.1 Introduction 
It is generally acknowledged that there is less knowledge about the sigma 2 receptor as 
opposed to the sigma 1 receptor due to the lack of high-affinity, selective ligands (Berardi 
et al., 2004). The sigma 2 receptor has not been cloned as the sigma 1 receptor has (Abate 
et al., 2011). Lack of knowledge surrounding sigma 2 receptors, however, does not bear 
any relationship to the importance of the sigma 2 receptors. In fact, sigma 2 receptor 
ligands have been studied for treatment of pancreatic cancer because they are 
preferentially internalized by proliferating cells and induce apoptosis; multiple sigma 2 
receptor ligands, even up to 10 nM affinity, are shown to decrease tumor burden in 
preclinical models of human pancreatic cancer (Hornick et al., 2012).  Interest in sigma 2 
receptors has been increasing especially since sigma 2 receptors are overexpressed in a 
wide variety of human tumor cell lines, representing biomarkers for the diagnosis of 
tumors with non-invasive techniques such as Positron Emission Tomography (PET ) or 
Single Photon Emission Computed Tomography (SPECT) (Abate et al., 2011).  
Therefore, finding high-affinity, selective sigma 2 ligands is on the rise, however known 
sigma 2 receptor ligands generally exhibit a poor selectivity profile, particularly over the 
sigma 1 receptor (Berardi et al., 2003).  Many of the researchers in the literature have 
synthesized and studied sigma 2 receptor ligands; comparatively, the affinity values to 
the sigma 1 receptor ligands are much higher. There is a focus on increased selectivity, 





sigma 1 ligands, there seems to be increased emphasis on the concept of selectivity to 
ensure there is not competition from sigma 1 ligands in the radioligand studies (Berardi et 
al., 2004; Fan et al., 2011; Hajilour et al., 2011;). 
Though the Gund group has done some pharmacophore and CoMFA studies on sigma 
2 receptor ligands through theses, published models in scholarly journals do not exist as 
they do for the sigma 1 receptor ligands at this time. Some comparison to the theses’ 
models exist in Section 4.4.1 as well as to a representative external model. 
 
4.2 Selection of Ligands 
Overall sigma 2 receptor ligands in the present study were selected based on compounds 
that were shown to be active for sigma 2 while also being selective for sigma 2. Naturally 
all of the studies used radioligand competitive binding assays with [
3
H]-DTG along with 
(+)-pentazocine to block sigma binding sites (Berardi et al., 2004; Fan et al., 
2011Hajilour et al., 2011;).  
Compounds 1-18 for sigma 2 receptor ligands were selected especially due to the fact 
that PB28, a sigma 2 receptor ligand with very high affinity (0.34 nM, compound 5), is a 
member of this class; therefore it is quite fitting to study derivatives of 1-
Cyclohexylpiperazine to determine if those compounds will yield similar binding 
affinities or selectivities (Berardi et al., 2004). Additionally, Wirpsza and Patel had used 
several of these molecules in their modeling studies as part of the earlier work on sigma 2 
receptor ligands with the Gund group (Wirpsza, 2008; Patel, 2010) The series studied in 







Table 4.1 Binding and Functional Data of 4-(Tetralin-1-yl) and 4-(Naphthalen-1-yl)alkyl 
Derivatives of 1-Cyclohexylpiperazine  
 
   
 
Compound  R R1 n σ1Ki(nM)  σ2Ki(nM)   σ1/ σ2  σ2/ σ1 
 
1  A 5-OCH3 0 0.40 ± 0.02 7.90 ± 1.60   20  
 
2  A 5-OCH3 1 0.31 ± 0.10 16.4 ± 4.2    53  
 
3  A 5-OCH3 2 1.57 ± 0.41 21.1 ± 3.4    13  
 
4  A H 3 0.61 ± 0.08 0.68 ± 0.03   1.1  
 
5*  A 5-OCH3 3 13.6 ± 1.9  0.34 ± 0.02 40    
 
6  A 6-OCH3 3 0.36 ± 0.12 5.42 ± 0.64   15  
 
7  A 7-OCH3 3 9.04 ± 1.02 1.22 ± 0.17 7.4   
 
8  A H 4 0.036 ± 0.015 14.6 ± 3.7    406  
 
9  A 5-OCH3 4 1.54 ± 0.36 3.58 ± 0.55   2.3  
 
10  A H 5 1.45 ± 0.35 7.85 ± 0.49   5.4  
 
11  A 5-OCH3 5 1.52 ± 0.63 0.35 ± 0.09 4.3    
 
12  A 5-OCH3 6 3.07 ± 0.70 103 ± 23    34  
 
13  A 5-OH 3 5.40 ± 0.40 2.66 ± 0.66 2    
 
14  A 6-OH 3 0.69 ± 0.05 1.12 ± 0.17   1.6  
 
15  B H 3 2.16 ± 0.63 0.69 ± 0.08 3.1   
 
16  B OCH3 3 1.57 ± 0.15 9.24 ± 1.37   5.9 
 
17  B H 4 0.22 ± 0.03 30.5 ± 8.7    139  
 
18  B H 5 2.40 ± 0.47 0.57 ± 0.08 4.2    
 
 
*Indicates included in the comprehensive sigma 2 pharmacophore derivation. 







dimethoxy-benzamide (compound 19) is one of the most potent and selective sigma 2 
receptor ligands reported with 8.2 nM affinity accompanied by 1573-fold selectivity over 
sigma 1 sites (Fan et al., 2011). Therefore, it is important to conduct molecular modeling 
on this molecule, compound 19, along with a series of new analogs where the amine ring 
fused to the aromatic ring was varied in size (Fan et al., 2011). These molecules, 
compounds 19 – 28, are located in Table 4.2. 
 
Table 4.2 Binding and Functional Data of Substituted Aminobutyl-benzamides   
   
          19    20                                     21 
 
   
  22     23   24 
 
 









Table 4.2 (continued) Binding and Functional Data of Substituted Aminobutyl-
benzamides   
   




Compound     σ1Ki(nM)  σ2Ki(nM)   σ1/ σ2 
  
 
19*     12,900   8.2   1573  
 
20     881 ± 15                  2.7 ± 0.1  326  
 
21     880 ± 60  4616 ± 247  0.2  
 
22     1442 ± 88  0.82 ± 0.06  1758  
 
23     5073 ± 82  734 ± 50  8.5  
 
24     4521 ± 45  9681 ± 522  0.47  
 
25     2068 ± 60  315 ± 15  6.58 
  
 
26     2564 ± 175  8957 ± 335  0.29 
   
 
27     4499 ± 182  5823 ± 224  0.77  
 
28     583 ± 28  2126 ± 240  0.27 
 
*Indicates included in the comprehensive sigma 2 pharmacophore derivation. 






 Compounds 29-37 represent molecules where the contribution of electron-
donating and electron-withdrawing groups were explored through synthesis and 
characterization of new compounds featuring a benzamide moiety and an isoquinoline 
moiety linked by an alkyl chain (Hajipour et al., 2011). Hajipour and coworkers focused 
on the concept of improving selectivity for the sigma 2 receptor (2011). These molecules 
are in Table 4.3. 
 
Table 4.3 Binding and Functional Data of Benzamide-isoquinoline Derivatives  
    
        29     30    31 
    
       32            33             34 
   
        35        36              37 

















Compound   σ2Ki(nM)  σ1Ki(nM)   σ1/ σ2   
 
29   26.78 ± 2.92               10,320 ± 363     385  
 
30   12,930 ± 55.77  7,870 ± 264  0.61  
 
31   866.70 ± 138.6  74,680 ± 305  86.17  
 
32   4,000 ± 177.9  11,200 ± 469  2.80  
 
33   1,400 ± 286  67,800 ± 4.155  48.40  
 
34   5,290 ± 408  >10
7
    
 
35   152,000 ± 4,106  14,690± 1,121  0.096   
 
36   >10
7 
  1.21 × 10
6 
 0.29    
 
37*   21.26 ± 2.41  87.5 ± 3.07  4.12  
 
*Indicates included in the comprehensive sigma 2 pharmacophore derivation. 
Source: Hajipour et al., 2011. 
 
Some of the work in the 1990s included comparison of binding parameters for 
sigma 1 and sigma 2 in rat and guinea pig brain membranes using a trishomocubane 
series by Nguyen and colleagues (Nguyen et al., 1996). Some molecules from this series 
were included in this work so that an additional sigma 2 class could be included, 
especially since the series was studied by Jung during the earlier work on sigma 2 for the 
Gund group (Jung, 2004). Also, reference compound 57 discussed later in this section is a 
trishomocubane derivative compound which is another reason why it is fitting to include 
several other molecules from the series. Table 4.4 summarizes the subset of 







Table 4.4:   Trishomocubane Subset of Compounds 
n = 1 
Compound   X  Y σ2Ki(nM) σ1Ki(nM)   σ1/ σ2 
  
 
38   OCH3  H 136 ± 19 103 ± 1   0.76 
 
39   H  Cl  30 ± 1  186 ± 8   6.2 
 
 
40   H  Br 40 ± 22  208 ± 13  5.20 
 
 
41   H  I 54 ± 18  169 ± 10  3.13 
 
42   H  CH3 108 ± 6   97 ± 6   0.90 
 
 
Source: Nguyen et al., 1996. 
 
In previous work by the Gund group, a large series of 1-aralkyl-4—
benzylpiperazine derivatives was studied by both Wirpsza and Patel based on Costantino 
and coworkers’ research (Costantino, 2004; Wirpsza, 2008; Patel, 2010). A subset of 
seven molecules, presented in Table 4.5, were chosen to include from the previous Gund 
work in order to build on the foundation of the sigma 2 studies, expanding the sigma 2 














Compound   R   σ2Ki(nM) σ1Ki(nM)  σ1/ σ2   
 
43     1.70  0.80  0.47 
 
44     1.48  0.30  0.20 
 
45*     1.59  0.30  0.19 
 
 
46     3.02  0.30  0.10 
 
47     25.6  15.4  0.60 
 
48     4.75  1.20  0.25  
 
49     5.35  2.66  0.50 
 







Several reference molecules were included in the pharmacophore derivation for 
the sigma 1 representative pharmacophore and CoMFA studies as explained in Chapter 3. 
Similarly, three rigid references were added to the dataset for the sigma 2 ligand models. 
The references previously used by the Gund group for sigma 2, also used in the current 
study, are shown in Table 4.6. Also note that Haloperidol, compound 53, was included as 
an additional flexible molecule as a means to later (in Chapter 5) compare the differences 
between sigma 1 and sigma 2  since it is active for both; it was included in the sigma 1 set 
in Chapter 3. Therefore, Haloperidol was used in the test set for both sigma 1 and sigma 2 
and was not used as a molecule in the construction of the CoMFA model. This is a key 
point because the activity data varied for this molecule in various studies by researchers. 
The data included in Table 4.6 for Haloperidol is not from Gund (2003) as in the sigma 1 
analysis for Chapter 3; instead more recent data was used for sigma 2 ligand studies by 
Fan et al., especially because the aminobutyl-benzamide series, studied in this work and 
included in the models, came from the same study (2011). The activity data served as a 







Table 4.6:   Binding and Functional Data of Reference and Other Compounds 
   




     
52  ANSTO-19 (Trishomocubane Derivative)  53  Haloperidol    
 
 
Compound   σ2Ki(nM) σ1Ki(nM)  σ1/ σ2   
 
50*   13.4 ± 2.0 7436 ± 308 554.93 (Berardi et al., 2004) 
 
51*   32 ± 15.2 6300    - (Bonhaus et al., 1993) 
 
52*   20 ±  4  152 ± 1  7.60 (Nguyen et al., 1996) 
 
53   9.58 ± 0.98 0.83 ± 0.03 11.5 (Fan et al., 2011) 
 
*Indicates included in the comprehensive sigma 2 pharmacophore derivation. 











4.3 Materials and Methods 
All molecules were initially drawn in Spartan ’14 and then optimized at the HF/6-31G* 
and B3LYP/6-31G* levels prior to being imported into the SYBYL-X 2.1 program. 
Molecular databases were created within SYBYL-X 2.1 to represent each class of 
compounds for the sigma 2 receptor ligands. DISCOtech, a tool within SYBYL-X 2.1, 
was then used to generate pharmacophores for each of the classes. Pharmacophore 
development for each set of selected molecules was conducted by utilizing the options 
within DISCOtech for feature selection (binding site), conformer searches, etc. to yield 
potential pharmacophore models. Following the development of pharmacophore models 
for each class, a database was created to include the most active/lead compounds with 
some rigid references and active references from the previous work by Gund and 
colleagues. This database was then utilized to develop a comprehensive pharmacophore 
to represent all of the sigma 2 ligand classes studied in this work. Once pharmacophore 
models were completed, the Comparative Molecular Field Analysis models were created 
for the sigma 2 molecules calculated at HF/6-31G* and B3LYP/6-31G* levels, 
respectively. Note that that the approach described in Chapter 3 for the sigma 1 ligands 
utilized in the CoMFA models was slightly different for sigma 2 ligands since the 
bioactivities varied so much; therefore the most active compounds from each of the 
classes were selected to yield a training set range between 3 and 4 log units (similar to the 
range for sigma 1 ligands in Chapter 3) since some of the activities for the molecules for 
sigma 2 were extremely poor. New ligands were designed once the CoMFA models were 
determined to meet robust criteria; contour maps generated from the CoMFA models 





pharmacophore derivation, CoMFA and design of new ligands are in Sections 4.4, 4.5, 
and 4.6, respectively. 
4.4 Pharmacophore Derivation 
DISCOtech allows the researcher to manually select the binding features of each 
molecule to be considered for pharmacophore generation. For these classes, hydrophobic 
groups, positive nitrogen and lone pair were used. This was done via an iterative process. 
First, models were explored without constraints or features selected, and gradually 
various combinations of binding groups were included.  Specifics regarding each class 
and the derivations are discussed in Section 4.4.1.  
 
4.4.1  Pharmacophore Models 
Pharmacophores were generated using DISCOtech in SYBYL-X 2.1 for each class of 
compounds and are shown as labelled in Figures 4.1 through 4.15. Similar to sigma 1, the 
main binding sites are the nitrogen site, the lone pair of electrons and a hydrophobic 
group, however an additional hydrophobic group was also used as a binding site on the 
opposite side of the N atom, producing a modified “pyramid” type pharmacophore with 
the exception of one class; the substituted benzamide-isoquinolines had a “triangle” type 
pharmacophore, however with different distances than observed in the sigma 1 work. The 
comprehensive pharmacophore to represent all of the sigma 2 classes studied in this work 
are in Figures 3.16 through 4.18. The distances for the 4-point pharmacophore are noted 
in the figures with more discussion around the comprehensive pharmacophore. 
 Figures 4.1 – 4.3 depict the pharmacophore development for the 18 molecules of 





greatly and therefore the hydrophobic point for the phenyl groups, on the side with the 
additional CH2 groups in-between, is seen among the chains/phenyl rings on the side of 




Figure 4.1 DISCOtech pharmacophore derivation of 1-cyclohexylpiperazines 
(compounds 1-18, hydrogen atoms hidden). Purple sphere = lone pair, red sphere = N 








Figure 4.2 DISCOtech pharmacophore derivation of 1-cyclohexylpiperazines 
(compounds 1-18), overlay with compound 5, PB 28 (hydrogen atoms hidden). Purple 




Figure 4.3 DISCOtech pharmacophore derivation of 1-cyclohexylpiperazines 










The aminobutyl-benzamide pharmacophore development is shown in Figures 4.4 - 4.6. 
These molecules have a similar pharmacophore to the previous class with the 1-
cyclohexylpiperazines, however the lengths between the binding groups (hydrophobic/N 
atoms) are generally longer due to the fact that the molecules are a long series. The 6 
molecules with highest bioactivity values were used for this series, as some of the activity 
values were extremely poor. 
 
Figure 4.4 DISCOtech pharmacophore derivation of substituted aminobutyl-benzamides  
(compounds 19, 20, 22, 23, 25, and 28, hydrogen atoms hidden). Purple sphere = lone 
pair, red sphere = N atom and green spheres = hydrophobic points. 
 
 
Figure 4.5 DISCOtech pharmacophore derivation of substituted aminobutyl-benzamides, 
overlay with compound 20 – hydrogen atoms hidden . Purple sphere = lone pair, red 







Figure 4.6 DISCOtech pharmacophore derivation of substituted aminobutyl-benzamides  
(compounds 19-28). Purple sphere = lone pair, red sphere = N atom and green spheres = 
hydrophobic points. 
 
Figures 4.7 – 4.9 depict the pharmacophore development for the benzamide-isoquinoline 
series. The series consisted of mostly poor activities, with the exception of  two 
molecules with high bioactivity, which may account for the difficulty in modeling the 
pharmacophore. It was found that a three point pharmacophore was more appropriate for 
this class specifically; the hydrophobic area on the other side of nitrogen, when chosen as 








Figure 4.7 DISCOtech pharmacophore derivation of substituted benzamide-isoquinoline 
derivatives (compounds 29-37, hydrogen atoms hidden). Purple sphere = lone pair, red 




Figure 4.8 DISCOtech pharmacophore derivation of substituted benzamide-isoquinoline 
derivatives (compounds 29-37), overlay with compound 37 - hydrogen atoms hidden. 









Figure 4.9 DISCOtech pharmacophore derivation of substituted benzamide-isoquinoline 
Derivatives (compounds 29-37). Purple sphere = lone pair, red sphere = N atom and blue-
green sphere = hydrophobic point. 
 
 
Figures 4.10 - 4.12 present another pyramid-type pharmacophore, in this case for the 
trishomocubane series, however the distances between the N and hydrophobic groups is 
much smaller as compared to the previous sigma classes studied thus far.  
 
Figure 4.10 DISCOtech pharmacophore derivation of substituted trishmocubane subset 
(compounds 38-42, hydrogen atoms hidden). Purple sphere = lone pair, red sphere = N 







Figure 4.11 DISCOtech pharmacophore derivation of substituted trishmocubane subset 
(compounds 38-42), overlay with reference molecule compound 52 (hydrogen atoms 





Figure 4.12 DISCOtech pharmacophore derivation of substituted trishmocubane subset 
(compounds 38-42). Purple sphere = lone pair, red sphere = N atom and blue/green 








Figures 4.13 through 4.15 present the pharmacophore model for 1-aralkyl-4-
benzylpiperazine derivatives studied in this work. Similarly, it presents a 4-point 
pharmacophore, however, the distances between the N atom and hydrophobic groups are 
a little less than the earlier classes (with the exception of the trishomocubanes), though 
there is the question of the hydrophobic area being the area before the phenyl or whether 
it is the phenyl ring (which would mean a slightly longer distance). The model developed 
here was the “cleanest” version with very good overlap for the conformers generated by 
DISCOtech. Note that it is slightly different in molecule conformation (overall) vs the 
previous molecules; though the pharmacophore is a pyramid-type, the piperazine is not as 
“straight” as noted for the other cyclohexyl-type rings in previous molecules. In fact, the 
way the piperazine piece lines up is similar to the close alignment of the N atoms 
observed in the sigma 1 pharmacophore development and CoMFA studies, which may 
explain why this class also shows high activity for sigma 1. Some of the other classes in 
this study for sigma 2 are more selective for sigma 2 than sigma 1. 
 
Figure 4.13 DISCOtech pharmacophore derivation of 1-aralkyl-4-benzylpiperazine 
derivatives subset (compounds 43-49, hydrogen atoms hidden). Purple sphere = lone pair, 







Figure 4.14 DISCOtech pharmacophore derivation of 1-aralkyl-4-benzylpiperazine 
derivatives subset (compounds 43-49), overlay with compound 43 - hydrogen atoms 




Figure 4.15 DISCOtech pharmacophore derivation of 1-aralkyl-4-benzylpiperazine 
derivatives subset (compounds 43-49). Purple sphere = lone pair, red sphere = N atom 
and blue/green spheres = hydrophobic points. 
 
Figures 4.16 – 4.18 represent the comprehensive pharmacophore development for sigma 
2, where lead compounds were selected from each class along with some rigid references 
to yield a representative pharmacophore for the sigma 2 subtype; the compounds chosen 
were compounds 5, 19, 37, 45, 50, 51 and 52. Compound 5, PB 28 – the most active 
sigma 2 ligand – was used as the reference in the pharmacophore generation in 





whereas the distance between the N atom and one hydrophobic point is 2.9 Å and the 
other distance is 5.47 Å. The other part of the triangle piece, on the opposite side of 5.47 
Å length is 6.37 Å, the distance between the lone pair and the hydrophobic point, whereas 
the distance between the lone pair and the phenyl group on the right side of the figures is 
4.8 Å. The distance between the two hydrophobic groups  is 8.17 Å. As discussed during 
the 1-aralkyl-4-benzylpiperazine model explanation, generally the sigma 2 
pharmacophore does not depict close or directional overlay of the N from the 
cyclohexyl/piperazine piece of the molecules; in general there is a pharmacophoric point 
there, but it is also weighted by the two (instead of one) pharmacophoric hydrophobic 
points on either side or it. This is a key point because this pharmacophore shape was 
applied to the CoMFA studies for sigma 2 with successful results, as the models were 
considered robust by the criteria in Section 2.2.2. Therefore, it seems that the main 
difference between the sigma 1 and sigma 2 pharmacophores is the matter of 3-points vs 
4 points due to the additional hydrophobic group. This was observed visually in the 
sigma 2 CoMFA alignments in Figures 4.23 and Figures 4.24 where the hydrophobic 
groups are more clearly clustered on both sides of the N as opposed to only the one 










Figure 4.16 Comprehensive DISCOtech pharmacophore derivation for Sigma 2 
(compounds 5, 19, 37, 45, 50, 51 and 52 – hydrogen atoms hidden). Purple sphere = 





Figure 4.17 Comprehensive DISCOtech pharmacophore derivation for Sigma 2, overlay 
with compound 5 (hydrogen atoms hidden). Purple sphere = acceptor site, red sphere = 








Figure 4.18 Comprehensive DISCOtech pharmacophore derivation for Sigma 2. Purple 




The current comprehensive pharmacophore model for sigma 2 in Figures 4.16 through 
4.18 was compared with previous sigma 2 pharmacophores from the Gund group. Patel 
had a three-point pharmacophore, which encompasses part of the current pharmacophore, 
with the N atom and hydrophobic group (2010). Figure 4.19 highlights some similarities 















Figure 4.19 Comparison of Comprehensive DISCOtech pharmacophore (a) from Figure 
4.17 with pharmacophore derived by Patel (b). 
 
Source: (b)  Patel, 2010 
 
The current comprehensive pharmacophore model for sigma 2 in Figures 4.16 through 
4.18 was compared to Jung’s model. Jung had a three-point pharmacophore, which 
encompasses part of the current pharmacophore, with the N atom and hydrophobic group 









Figure 4.20 Comparison of Comprehensive DISCOtech pharmacophore (a) from Figure 
4.17 with pharmacophore derived by Jung (b). 
Source: (b)  Jung, 2003 
 
The current comprehensive pharmacophore model for sigma 2 in Figures 4.16 through 
4.18 was compared to Wirpsza’s model . Wirpsza had a four point pharmacophore, 
similar to the current pharmacophore (2008). Note that nearly all the distances are very 
close with the exception of the distance between the hydrophobic groups. This can be 
explained by the fact that compound 5, PB 28, was used as the reference for the current 
work since it was deemed to be the most active compound for sigma 2, whereas Wirpsza 
used the default reference in DISCOtech which could mean a smaller distance between 
the hydrophobic groups if that molecule was not as active. Figure 4.21 highlights the 














Figure 4.21 Comparison of Comprehensive DISCOtech pharmacophore (a) from Figure 
4.17 with pharmacophore derived by Wirpsza (b). 
Source: (b)  Wirpsza, 2008 
 
This study aimed to resolve the model differences from the past by the Gund group and 
was able to do so successfully; the current pharmacophore in Figures 4.16 – 4.18 could 
be considered a “hybrid” model which includes aspects of all of the other models, 
including all of the classes the other researchers studied while using the most active 
reference for DISCOtech to yield a more representative, active pharmacophore model. 
This model was compared with those seen in the literature. Rhoades and colleagues 





note that the other models they compared with from other researchers were very 
molecule/class-specific (Rhoades et al., 2014). Therefore, the researcher for this study 
compared with Rhoades’ model who aimed to develop a representative sigma 2 
pharmacophore (2014). The work done by Rhoades and colleagues was very extensive, 
with approximately 100 pharmacophore models which they ranked, clustered and 
analyzed (Rhoades et al., 2014). Figure 4.22 is the best model for comparison for our 
case, as “Group 2” as explained, was the best ranked as it had ties to analysis yielding 
high q
2
 values, however the application of the robust criteria was not explicitly observed 
in the paper (it is unclear if it had been performed as there is no mention to Golbraikh and 
colleagues, however other statistical values were calculated and discussed) (Rhoades et 
al., 2014). Nevertheless, Figure 4.22 depicts two pharmacophores by Rhoades and 
colleagues with some similarity around P1 (positive nitrogen), however the hydrophobic 
point locations are different and they have chosen donor sites, not an acceptor site 
associated with the N atom as chosen in this study. The approach Rhoades and colleagues 
took was different than the one taken here where they do not have a very active molecule 
such as PB 28 in the study. Further, the energy/calculation levels associated with the 
QSAR/electrostatics taken by Rhoades is not clear.  Each researcher has a different 
approach and therefore there are variations in the models. From the current work, the 
leading pharmacophore in Figure 4.16 – 4.18 is postulated, especially since it was applied 









Figure 4.22 Pharmacophore models by Rhoades and colleagues. R1 = aromatic, H1/H2 = 
hydrophobic, D1/D2 = donor sites and P1 = positively charged site. 




4.5 Comparative Molecular Field Analysis 
4.5.1 Geometry Optimization and Electrostatic Studies 
Each molecule in this study was optimized and saved at the ab initio HF/6-31G* and 
density functional B3LYP/6-31G* levels with electrostatic charges corresponding to each 
calculation level. Once each molecule was optimized, it was saved as a “.mol2” file with 
“electrostatic” to carry the corresponding geometry and calculated electrostatic charges 









4.5.2 Alignment  
Alignment of the HF/6-31G* and B3LYP/6-31G* optimized geometries for the sigma 2 
ligands was an essential step in generating a CoMFA model for each calculation level, 
respectively. A key point is that this was a rigid alignment approach with the intent to 
maintain the bound conformation of each molecule at the calculation level being studied. 
Many researchers, however, use flexible alignment approaches; as an example, Caballero 
and researchers state that their 3D-QSAR models rely on the arbitrary alignment of 
conformationally flexible ligands (2012).  Since part of the objective of this study was to 
observe the results, comparing ab initio with density functional methods, and also since 
the conformation is unknown for each molecule when it binds to the sigma 2 receptor, the 
assumption was made that the energy should be minimized. Therefore the ab initio and 
density functional methods calculated energy minimized geometries while also 
calculating the electrostatic charges.  The resulting molecules were then rigidly aligned to 
each other. 
The approach to alignment for the sigma 2 ligands consisted of first applying the 
DISTILL RIGID tool for the 1-aralkyl-4-benzylpiperazine molecules since those 
conformations were very close visually and therefore very tight alignment could be 
initiated for the sigma 2 ligands with that class. Then compound 5 (PB 28), considered 
the template molecule overall for the CoMFA alignment especially since it was the 
reference compound in the comprehensive pharmacophore model, was aligned with the 
already aligned 1-aralkyl-4-benzylpiperazine class. Then DISTILL RIGID was applied to 
the 1-cyclohexylpiperazines. The lead compound from the benzamide-isoquinoline 





lead via ALIGN DATABASE. The same approach was taken for the aminobutyl-
benzamides. Trishmocubanes were aligned via the nitrogen atom to compound 5. 
References were similarly aligned via the “match atoms” function using the N and 
surrounding carbon atoms. Then the benzamide-isoquinoline derivatives  were further 
aligned via the “match atoms function” choosing the phenyl ring and N and surrounding 
carbon atoms. The q
2
 for HF/6-31G* and B3LYP/6-31G* were 0.528 and 0.544, 
respectively. 
Consistent with the robust criteria described in Section 2.2, 5 molecules were 
chosen as the test set with the remaining 26 molecules acting as the training set. 
Additional details are provided in Section 4.5.3. The final alignment of all 31 molecules 
can be viewed in Figure 4.23 for HF/6-31G* and Figure 3.24 for B3LYP/6-31G*. The 
resulting alignments led to robust models as described in Section 2.2.2. Additional details 








Figure 4.23 Alignment of all 31 sigma 2 ligands at the HF/6-31G* calculation level.  
 
 






4.5.3 Quantitative Structure Activity Data Analysis 
The CoMFA models were initiated by first conducting the molecular alignment as 
described in Section 4.5.2. Each activity (Ki) value was converted to a pKi value using 
Equation 2.4. The training set for the CoMFA ensured a range of at least 3 log units in 
terms of pKi, as is suggested in the field and demonstrated by other researchers (Bolden 
et al., 2013). The training set ranged from -3.1462 to 0.4685 whereas the test set ranged 
from -2.9379 to -0.48 log units. The histograms of the pKi vs number of molecules are 
shown in Figures 4.25A and 4.25B. 
 







Figure 4.25B Histogram of frequency vs pKi for sigma 2 ligands in test set. 
 
 The CoMFA models were constructed using the default settings in SYBYL-X 2.1. 
Therefore, an sp
3
 hybridized carbon atom was probed with a +1.0 unit charge which 
extended at least 4 Å beyond each molecule, 2.0 Å grid spacing and the default 30 
kcal/mol energy cutoff for steric and electrostatic fields. The CoMFA column, combined 
with the literature pKi values, generated the Partial Least Squares cross-validated q
2
 for 
each set, resulting in a predicted bioactivity (pKi) value for each training set molecule. 
The test set, molecules which were not used to create the model, was used to validate the 
model by comparing predicted bioactivities generated with the experimental results. The 
resulting sigma 1 dataset at HF/6-31G* with 36 molecules in the training set resulted in a 
q
2





resulting sigma 1 dataset at B3LYP/6-31G* with 26 molecules in the training set resulted 
in a q
2 
value of 0.544; the predicted bioactivity values for that set is in Table 4.7. Table 





Table 4.7: Experimental and Predicted Bioactivities (pKi) by the Training Set of 
Sigma 2 Compounds using ab initio and Density Functional Calculation Methods 
 
Compounds             Lit. pKi         HF/6-31G*  B3LYP/6-31G*  
 








































































































































































































Table 4.8: Experimental and Predicted Bioactivities (pKi) by the Test Set of Five 
Sigma 2 Compounds using ab initio and Density Functional Calculation Methods 
 
Compounds             Lit. pKi         HF/6-31G*  B3LYP/6-31G*  
 







































The Partial Least Squares Analysis (PLS), as described in Section 2.2.1, was used 
by applying the SAMPLS algorithm in SYBYL-X 2.1 developed by Bruce Bush. The 
optimum number of components was determined by the SYBYL-X 2.1 in the output 
report from the SAMPLS algorithm and is shown in bold in Table 4.8. For the HF/6-
31G* calculation level, the QSAR module used 2 components for the model, however 
SAMPLS, during the PLS application, stated 4 components was the optimum. In this case 
the originally chosen 2 component model was used, especially since the q
2
 value 
decreased at the next component addition as observed in Table 4.9. The number of 
optimal components identified in Table 4.8 was then applied without cross-validation 
yielding the results in Table 4.10. The R
2
 values for HF/6-31G* and B3LYP/6-31G* 
without cross-validation, using the optimal number of components for each, respectively, 
at 5 and 4 yielded 0.920 and 0.995. Note that Table 4.10 also presents the electrostatic 










Table 4.9: Optimal Component Number and q
2
 by “Leave-One-Out” using SAMPLS by 
the Training Set of 26 Molecules  
 
Lev. Term C. 1 C. 2 C. 3 C. 4 C. 5 C. 6 C. 7 C. 8 C. 9 C. 10 




  0.387 0.528 0.517 0.531 0.525 0.503 0.492 0.469 0.457 0.458 
            B3 s.e.e. 0.762 0.728 0.724 0.727 0.726 0.734 0.751 0.780 0.809 0.842 
  q
2
  0.374 0.453 0.481 0.501 0.527 0.540 0.544 0.535 0.530 0.522 
s.e.e. is standard error of estimates. 
 
Table 4.10: QSAR Reports by Non-Crossvalidation Using SAMPLS by the Training 





 F Values Steric. Electro. 
HF/6-31G* 0.279 0.920 (n1 = 2, n2 = 23) 131.471 0.422 0.578 
B3LYP/6-31G* 0.080 0.995 (n1 = 7, n2 = 18) 499.198 0.393 0.607 
s.e.e. is standard error of estimates.  
 
The application of the robust criteria as described in Section 2.2.3 is shown in Figures 
4.26 and 4.27 for HF/6-31G* in the graphs of predicted pKi values vs experimental pKi 
values. The training set and tests were subject to Equations 2.5 – 2.9; those equations 
were used to calculate and confirm that the HF/6-31G* CoMFA model meets the robust 











Figure 4.27 Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA 































y = 0.679x - 0.3876 
R² = 0.9086 
 
y = 0.8628x 
R0² = 0.7856 
 
Training set: 
y = 1x - 2E-05 
R² = 0.9196 
 
y = 1.0862x 






























Table 4.11: Results for QSAR Robust Criteria Equations 2.5 – 2.9 for HF/6-31G* 
(Sigma 2) 
 
Equations (2.5 – 2.9) Value 
q
2















=  0.05 and 𝑘 = 1.09 
|R0
2 − R0
′2|  < 0.3 |R0
2 − R0
′2| = 0.08 
 
The application of the robust criteria as described in Section 2.2.3 is shown in Figures 
4.28 and 4.29 for B3LYP/6-31G* in the graphs of predicted pKi values vs experimental 
pKi values. The training set and tests were subject to Equations 2.5 – 2.9; those equations 
were used to calculate and confirm that the B3LYP/6-31G* CoMFA model meets the 











Figure 4.29 Graph of Experimental pKi vs Predicted pKi for Test Set by the CoMFA 






























y = 1x - 4E-06 




y = 0.6199x - 0.4606 
R² = 0.8589 
 
y = 0.8384x 




y = 1.0856x 































Table 4.12: Results for QSAR Robust Criteria Equations 2.5 – 2.9 for B3LYP/6-31G* 
(Sigma 2) 
 
Equations (2.5 – 2.9) Value 
q
2















=  0.06 and 𝑘 = 1.09 
|R0
2 − R0
′2|  < 0.3 |R0
2 − R0
′2| = 0.14 
 
In summary, the bioactivity prediction for both models at HF/6-31G* and B3LYP/6-
31G* were considered robust via PLS and the criteria set by Golbraikh and colleagues 
(2002, 2003). Therefore, the model can serve as a means to predict other compounds for 
sigma 2 activity.  
 
4.5.4 Contour Maps of CoMFA Models 
Contour maps from the CoMFA models were explored with the objective to understand 
the desired sterics and electrostatics that could enhance the activity of a molecule, 
enabling the design of new ligands. In the maps, green represents steric bulk desirable 
whereas yellow represents steric bulk undesirable. In terms of electrostatics, the maps 
depict red for negative charge desirable whereas blue represents positive charge as 
desirable. The differences observed in the CoMFA contour maps between HF/6-31G* 
and B3LYP/6-31G* were also explored.  
Figure 4.30 and Figure 4.31 show the contour maps for compound 5 (PB 28), 





for the DISCOtech pharmacophore generation for the representative sigma 2 model. The 
right side of Figures 4.30 and 4.31 show that electronegativity is preferable above the 
cyclohexyl as well as bulk surrounding that area; on the left side it shows bulk around the 
rings as well as a mix of positive and negative charge desirable. The calculation levels for 
the CoMFA contour maps appear to be in good agreement visually. 
 
 












The CoMFA contour maps for compound 19 were observed, as this molecule, based on 
its aforementioned extremely high selectivity for sigma 2, is an excellent candidate for 
bioactivity improvement. Figures 4.32 and 4.33 demonstrate the possibilities to add 
electronegativity on the right side as well as bulk, in addition to there being opportunities 















4.6  Design of New Sigma 2 Ligands 
 
Utilizing the analysis conducted in Section 4.5.4, the design of new ligands was 
conducted on compound 19, with various combinations to increase electronegativity or 
positivity as well as bulk in various locations. There were four main locations 
considered based on the CoMFA contour maps as shown in Table 4.13, with improved 
bioactivity values noted in bold. Note that the literature pKi for compound 19 is  
-0.9138. 
 
Table 4.13: Compound 19-based New Ligands 
 
 
Comp. R1 R2 R3 R4 HF/6-31G* 
B3LYP/ 
6-31G* 
     
Predicted pKi 
19 H CH3 H H -0.7067 -0.9242 
53 Cl CH3 H H -0.2655 -0.4803 
54 Cl tbutyl H H -0.1777 -0.3961 
55 COOH CH2-NH2 NH2 H -0.3564 -0.4336 
56 COOH CH3 H H -0.3028 -0.6155 
57 H tbutyl H H -0.5156 -0.833 
58 F CH3 H H -0.2448 -0.6145 
59 H CH3 NH2 H -0.7367 -0.6311 
60 H CH2-NH2 H H -0.4522 -0.4811 
61 Cl C(CH3)(CH2NH2)(CH2NH2) H H -0.6485 -1.1311 









The best R-group combinations, yielding highest activity improvements, were selected 
for discussion. In the case of adding bulk (tbutyl) at the R2 location and Cl at the R1 
location, the predicted pKi improved from -0.7067 to -0.1777 for HF/6-31G* and from -
0.9242 to -0.3961 for B3LYP/6-31G*. As explained in Chapter 3, higher pKi means 
increased bioactivity. A pKi value could mean a Ki value of 1.5 nM which is an 
improvement over the literature value of 8.2 nM for the molecule. The corresponding 












Figure 4.35 CoMFA contour map of compound 54 at B3LYP/6-31G*. 
 
 
Another promising combination, yielding high activity improvement, was the case of 
adding N atoms (increasing positivity) at R2 and R3. There was fairly good overlap of 
these additions into the blue areas of the contour map. The predicted pKi improved from  
-0.7067 to -0.3564 for HF/6-31G* and -0.9242 to -0.4336. The corresponding contour 


















The case of increasing electronegativity on the right cyclohexyl ring with the addition of 
a Cl atom helped increase bioactivity for compound 19 as well on both calculation levels 
as demonstrated with compound 58. The predicted pKi value went from -0.7067 to  
-0.2655 for HF/6-31G* and -.9242 and -0.4803 for B3LYP/6-31G*. The corresponding 












Figure 4.39 CoMFA contour map of compound 53 at B3LYP/6-31G*. 
 
 
Certainly these are promising results, lending to the possibility that the newly 
predicted highly active ligands could be synthesized and potentially used in the future as 
drug candidates, particularly as potentially highly selective sigma 2 compounds since 
these were designed from compound 19. Highly active, selective sigma 2 compounds are 
rare as evidenced by the data set and by other researchers. In fact, even compound 5, PB 
28, does not have a very high selectivity (σ1/ σ2): 40 vs 1573 for compound 19. Therefore, 
we can see the value for improving activity for compound 19; initial results were 
excellent with a possible high activity at 1.5 nM. Additional contour maps for newly 














COMPARISON OF SIGMA 1 AND SIGMA 2 RECEPTOR LIGANDS 
 
5.1 Sigma 1 and Sigma 2 Receptor Ligand Differences 
Part of the objective of this study was to determine what differentiates a ligand from 
being bioactive for a sigma 1 receptor vs a sigma 2 receptor. As mentioned in Chapter 3 
and 4, there were noted differences in the comprehensive pharmacophores. Figures 3.20 
and 4.18 represent the two different comprehensive pharmacophores. As stated, these 
pharmacophores drove the alignment techniques used for the corresponding CoMFA 
models which were considered robust and highly predictive for bioactivity. Therefore, 
one can presume that these pharmacophores generated by DISCOtech are viable models, 
in addition to the consistent framework they had from previous work in the Gund group. 
Particularly for sigma 2, the current model postulated resolves the previous models into a 
hybrid model and again shows strong representation for different classes of compounds, 










Figure 3.20 (repeat) Comprehensive DISCOtech pharmacophore derivation for Sigma 1. 





Figure 4.18 (repeat) Comprehensive DISCOtech pharmacophore derivation for Sigma 2. 
Purple sphere = acceptor site, red sphere = positive nitrogen and blue-green spheres = 
hydrophobic centers. 
 
The following Figures 5.1 - 5.4, demonstrate the test compound, Haloperidol, in the 
HF/6-31G* and B3LYP/6-31G* CoMFA contour maps. Interestingly, Haloperidol in 
sigma 1 maps appears to have slightly more distribution of bulk on both ends of the 
molecule and somewhat around the molecule. Haloperidol in sigma 2 maps, however, 





necessarily around the whole molecule. Further, sigma 2 appears to favor more positivity 
as evidenced by the color blue in the map.  
 
 






























SUGGESTIONS FOR FURTHER WORK 
 
Following the completion of the analysis around the sigma 1 and sigma 2 ligands studied 
in this work, the researcher concludes that the objectives of the study were met – from 
deriving pharmacophores for both receptor ligand subtypes, to designing comprehensive 
pharmacophores, to applying the designed comprehensive pharmacophores to the 
CoMFA alignments and models, to yielding robust CoMFA models and consequently 
useful contour maps which led to the understanding of the differences of sigma 1 and 
sigma 2 receptor ligands in addition to enabling the design of several new, highly 
bioactive ligands. Additionally, some comparison to previous work in the Gund group as 
well as other researchers’ models globally was conducted. 
 Future work should encompass delving further into the analysis around sigma 1 vs 
sigma 2. Now that these CoMFA models have been confirmed as highly robust and 
predictive, they could be used for additional screening work for design of new ligands or 
prediction of bioactivity for various molecules. For instance, perhaps molecules could be 
designed to shift to either sigma 1 or sigma 2 activity depending on the need. If that 
design process could yield successful results, then it would be clear that there is indeed 
understanding of the differences between sigma 1 and sigma 2. Further, the models could 
be used to test other compounds for sigma 1 or sigma 2 prior to being synthesized in the 
lab.  
 Many researchers appear to modify the design of a ligand by varying ring size or 





models or more importantly, consider the bulk and electrostatics according to the models 
for the design initially.  
Further work should be done to understand if flexible alignment is truly 
appropriate or sound. Many researchers claim this to be the case and in general the 
software programs expect that one will be mostly conducting flexible alignment. Perhaps 
some studies to conduct flexible alignment while measuring the energy differences and 
simultaneously comparing the results to the data generated here may be a first step in that 
process. 
Finally, pharmacophore and CoMFA models can be expanded to include 







ADDITIONAL CONTOUR MAPS FOR SIGMA 1 LIGANDS 
 
The figures in APPENDIX A represent additional contour maps of the lead compounds 



































































ADDITIONAL CONTOUR MAPS FOR SIGMA 2 LIGANDS 
 
The figures in APPENDIX B represent additional contour maps of the lead compounds 
for each sigma 2 class as well as the contour maps of the entire training set. 
 
 



















































ADDITIONAL CONTOUR MAPS FOR NEWLY DESIGNED SIGMA 2 
LIGANDS 
 
The figures in APPENDIX C represent additional contour maps of the newly designed 
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